1
|
van Velthoven MJJ, Gudde AN, Arendsen E, Roovers JP, Guler Z, Oosterwijk E, Kouwer PHJ. Growth Factor Immobilization to Synthetic Hydrogels: Bioactive bFGF-Functionalized Polyisocyanide Hydrogels. Adv Healthc Mater 2023; 12:e2301109. [PMID: 37526214 DOI: 10.1002/adhm.202301109] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2023] [Revised: 07/22/2023] [Indexed: 08/02/2023]
Abstract
With its involvement in cell proliferation, migration and differentiation basic fibroblast growth factor (bFGF) has great potential for tissue engineering purposes. So far, however, clinical translation of soluble bFGF-based therapies is unsuccessful, because the required effective doses are often supraphysiological, which may cause adverse effects. An effective solution is growth factor immobilization, whereby bFGF retains its bioactivity at increased efficacy. Studied carriers include films, solid scaffolds, and particles, as well as natural and synthetic hydrogels. However, these synthetic hydrogels poorly resemble the characteristics of the native extracellular matrix (ECM). In this work, bFGF is covalently conjugated to the synthetic, but highly biocompatible, polyisocyanide-based hydrogel (PIC-bFGF), which closely mimics the architecture and mechanical properties of the ECM. The growth factor conjugation protocol is straightforward and readily extrapolated to other growth factors or proteins. The PIC-bFGF hydrogel shows a prolonged bioactivity up to 4 weeks although no clear effects on the ECM metabolism are observed. Beyond the future potential of the PIC-bFGF hydrogel toward various tissue engineering applications, this work underlines that simple biological conjugation procedures are a powerful strategy to induce additional bioactivity in 3D synthetic cell culture matrices.
Collapse
Affiliation(s)
- Melissa J J van Velthoven
- Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, Nijmegen, 6525 AJ, The Netherlands
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 28, Nijmegen, 6525 GA, The Netherlands
| | - Aksel N Gudde
- Department of Obstetrics and Gynecology, Amsterdam University Medical Center, location AMC, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands
- Amsterdam Reproduction and Development, Amsterdam University Medical Center, location AMC, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands
| | - Evert Arendsen
- Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, Nijmegen, 6525 AJ, The Netherlands
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 28, Nijmegen, 6525 GA, The Netherlands
| | - Jan-Paul Roovers
- Department of Obstetrics and Gynecology, Amsterdam University Medical Center, location AMC, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands
- Amsterdam Reproduction and Development, Amsterdam University Medical Center, location AMC, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands
| | - Zeliha Guler
- Department of Obstetrics and Gynecology, Amsterdam University Medical Center, location AMC, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands
- Amsterdam Reproduction and Development, Amsterdam University Medical Center, location AMC, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands
| | - Egbert Oosterwijk
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 28, Nijmegen, 6525 GA, The Netherlands
| | - Paul H J Kouwer
- Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, Nijmegen, 6525 AJ, The Netherlands
| |
Collapse
|
2
|
van Velthoven MJJ, Gudde AN, Struijs F, Oosterwijk E, Roovers JP, Guler Z, Hooijmans CR, Kouwer PHJ. The Effect of Growth Factors on Vaginal Wound Healing: A Systematic Review and Meta-analysis. Tissue Eng Part B Rev 2023; 29:429-440. [PMID: 37051705 DOI: 10.1089/ten.teb.2022.0225] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/14/2023]
Abstract
Surgical outcomes of pelvic organ prolapse (POP) surgery are poor, resulting in a 20% recurrence risk. Following the hypothesis that impaired wound healing is the main determinant of recurrent POP, growth factors have the potential to promote wound healing and may improve surgical outcomes. In this study, we systematically reviewed the effect of growth factors on vaginal wound healing in both in vitro and animal studies. For each independent comparison, the standardized mean difference and 95% CI were calculated using the Hedges' g correction. Of the 3858 retrieved studies, seven studies were included, of which six were included in meta-analysis (three in vitro studies and four in vivo studies). In vitro, basic fibroblast growth factor (bFGF) promotes proliferation, differentiation, and collagen types I and III production. Epidermal growth factor stimulates proliferation and connective tissue growth factor promotes Tenascin-C expression. These effects, however, are less pronounced in vivo; only bFGF slightly promotes collagen production. The review shows that growth factors, particularly bFGF, are able to promote vaginal wound healing in vitro. The uncertain in vivo findings suggest that preclinical models should be improved. The ultimate goal is to develop effective growth factor-supplemented therapies that improve surgical outcomes for POP.
Collapse
Affiliation(s)
- Melissa J J van Velthoven
- Institute of Molecules and Materials, Radboud University, Nijmegen, The Netherlands
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Aksel N Gudde
- Department of Obstetrics and Gynecology and Amsterdam University Medical Center, Amsterdam, The Netherlands
- Amsterdam Reproduction and Development, Amsterdam University Medical Center, Amsterdam, The Netherlands
| | - Frederique Struijs
- Institute of Molecules and Materials, Radboud University, Nijmegen, The Netherlands
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Egbert Oosterwijk
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Jan-Paul Roovers
- Department of Obstetrics and Gynecology and Amsterdam University Medical Center, Amsterdam, The Netherlands
- Amsterdam Reproduction and Development, Amsterdam University Medical Center, Amsterdam, The Netherlands
| | - Zeliha Guler
- Department of Obstetrics and Gynecology and Amsterdam University Medical Center, Amsterdam, The Netherlands
- Amsterdam Reproduction and Development, Amsterdam University Medical Center, Amsterdam, The Netherlands
| | - Carlijn R Hooijmans
- Department of Anesthesiology, Pain and Palliative Care, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Paul H J Kouwer
- Institute of Molecules and Materials, Radboud University, Nijmegen, The Netherlands
| |
Collapse
|
3
|
Husch JF, Coquelin L, Chevallier N, Tiemessen DM, Oosterwijk E, van Rheden R, Woud C, Vossen J, Leeuwenburgh SCG, van den Beucken J. Comparison of osteogenic capacity and osteoinduction of adipose tissue-derived cell populations. Tissue Eng Part C Methods 2023; 29:216-227. [PMID: 37071134 DOI: 10.1089/ten.tec.2023.0039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/19/2023] Open
Abstract
Stromal vascular fraction (SVF) is the primary isolate obtained after enzymatic digestion of adipose tissue that contains various cell types. Its successful application for cell-based construct preparation in an intra-operative setting for clinical bone augmentation and regeneration has been previously reported. However, the performance of SVF-based constructs compared to traditional ex vivo expanded adipose tissue-derived mesenchymal stromal cells (ATMSCs) remains unclear and direct comparative analyses are scarce. Consequently, we here aimed to compare the in vitro osteogenic differentiation capacity of donor-matched SVF versus ATMSCs as well as their osteoinductive capacity. Human adipose tissue from 9 different donors was used to isolate SVF, which was further purified via plastic-adherence to obtain donor-matched ATMSCs. Both cell populations were immunophenotypically characterized for MSC, endothelial and hematopoietic markers after isolation and immunocytochemical staining was used to identify different cell types during prolonged cell culture. Based on normalization using plastic-adherence fraction determination, SVF and ATMSCs were seeded and cultured in osteogenic differentiation medium for 28 days. Furthermore, SVF and ATMSCs were seeded onto devitalized bovine bone granules and subcutaneously implanted into nude mice. After 42 days of implantation, granules were retrieved, histologically processed and stained with hematoxylin and eosin (HE) to assess ectopic bone formation. ATMSCs showed to be a homogenous cell population during cell culture, while SVF cultures consisted of multiple cell types. All donor-matched comparisons showed either accelerated or stronger mineralization for SVF cultures in vitro. However, neither SVF nor ATMSCs loaded on devitalized bone granules induced ectopic bone formation upon subcutaneous implantation, as opposed to control granules loaded with bone morphogenetic protein-2 (BMP-2) which triggered ectopic bone formation with 100% incidence. Despite the observed lack of osteoinduction, our findings provide important in vitro evidence on osteogenic superiority of intra-operatively available SVF as compared to donor-matched ATMSCs. Consequently, further studies should focus on optimizing the efficacy of these cell populations for implementation in orthotopic bone fracture or defect treatment.
Collapse
Affiliation(s)
- Johanna Fa Husch
- Radboudumc, Dentistry, Philips van Leydenlaan 25, Nijmegen, Netherlands, 6525EX;
| | - Laura Coquelin
- Université Paris Est, Faculté de médecine, Créteil, France
- Etablissement Français du Sang, Unité Ingénierie & Thérapie Cellulaire, créteil, France;
| | - Nathalie Chevallier
- Etablissement Français du Sang, Unité Ingénierie & Thérapie Cellulaire, 5 rue Gustave Eiffel, Site Henri Mondor, 5 rue Gustave Eiffel, Créteil, France, 94017 cedex;
| | - Dorien M Tiemessen
- Radboud University Medical Center, Nijmegen, The Netherlands, Urology, Geert Grooteplein Zuid 28, Nijmegen, Netherlands, 6525 GA;
| | | | - René van Rheden
- Radboudumc Afdeling Tandheelkunde, 370502, Nijmegen, Gelderland, Netherlands;
| | - Charlotte Woud
- Radboudumc Afdeling Tandheelkunde, 370502, Nijmegen, Gelderland, Netherlands;
| | - Jurriaan Vossen
- Radboudumc Afdeling Tandheelkunde, 370502, Nijmegen, Gelderland, Netherlands;
| | - Sander C G Leeuwenburgh
- Radboud University Nijmegen Medical Center, Biomaterials, Philips van Leydenlaan 25, Nijmegen, Netherlands, 6525 EX;
| | - Jeroen van den Beucken
- Radboudumc Department of Dentistry, 370502, Regenerative Biomaterials, ph v leijdenlaan 25, Nijmegen, Netherlands, 6525 EX
- Radboud University Radboud Institute for Molecular Life Sciences, 59912, Nijmegen, Netherlands, 6525 GA;
| |
Collapse
|
4
|
Yuan H, Liu K, Cóndor M, Barrasa-Fano J, Louis B, Vandaele J, de Almeida P, Coucke Q, Chen W, Oosterwijk E, Xing C, Van Oosterwyck H, Kouwer PHJ, Rocha S. Synthetic fibrous hydrogels as a platform to decipher cell-matrix mechanical interactions. Proc Natl Acad Sci U S A 2023; 120:e2216934120. [PMID: 37011188 PMCID: PMC10104511 DOI: 10.1073/pnas.2216934120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
Abstract
Cells continuously sense external forces from their microenvironment, the extracellular matrix (ECM). In turn, they generate contractile forces, which stiffen and remodel this matrix. Although this bidirectional mechanical exchange is crucial for many cell functions, it remains poorly understood. Key challenges are that the majority of available matrices for such studies, either natural or synthetic, are difficult to control or lack biological relevance. Here, we use a synthetic, yet highly biomimetic hydrogel based on polyisocyanide (PIC) polymers to investigate the effects of the fibrous architecture and the nonlinear mechanics on cell-matrix interactions. Live-cell rheology was combined with advanced microscopy-based approaches to understand the mechanisms behind cell-induced matrix stiffening and plastic remodeling. We demonstrate how cell-mediated fiber remodeling and the propagation of fiber displacements are modulated by adjusting the biological and mechanical properties of this material. Moreover, we validate the biological relevance of our results by demonstrating that cellular tractions in PIC gels develop analogously to those in the natural ECM. This study highlights the potential of PIC gels to disentangle complex bidirectional cell-matrix interactions and to improve the design of materials for mechanobiology studies.
Collapse
Affiliation(s)
- Hongbo Yuan
- Key Laboratory of Molecular Biophysics of Hebei Province, Institute of Biophysics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin 300401, China
- Molecular Imaging and Photonics, Chemistry Department, KU Leuven, Leuven 3000, Belgium
| | - Kaizheng Liu
- Molecular Imaging and Photonics, Chemistry Department, KU Leuven, Leuven 3000, Belgium
- Institute for Molecules and Materials, Radboud University, Nijmegen 6525 AJ, The Netherlands
- Research Center for Human Tissue and Organs Degeneration, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
| | - Mar Cóndor
- Department of Mechanical Engineering, Biomechanics section, KU Leuven, Leuven 3000, Belgium
| | - Jorge Barrasa-Fano
- Department of Mechanical Engineering, Biomechanics section, KU Leuven, Leuven 3000, Belgium
| | - Boris Louis
- Molecular Imaging and Photonics, Chemistry Department, KU Leuven, Leuven 3000, Belgium
- Division of Chemical Physics and NanoLund, Department of Chemistry, Lund University, 221 00 Lund, Sweden
| | - Johannes Vandaele
- Molecular Imaging and Photonics, Chemistry Department, KU Leuven, Leuven 3000, Belgium
| | - Paula de Almeida
- Institute for Molecules and Materials, Radboud University, Nijmegen 6525 AJ, The Netherlands
| | - Quinten Coucke
- Molecular Imaging and Photonics, Chemistry Department, KU Leuven, Leuven 3000, Belgium
| | - Wen Chen
- Institute for Molecules and Materials, Radboud University, Nijmegen 6525 AJ, The Netherlands
| | - Egbert Oosterwijk
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen 6500 HB, The Netherlands
| | - Chengfen Xing
- Key Laboratory of Molecular Biophysics of Hebei Province, Institute of Biophysics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin 300401, China
| | - Hans Van Oosterwyck
- Department of Mechanical Engineering, Biomechanics section, KU Leuven, Leuven 3000, Belgium
- Prometheus Division of Skeletal Tissue Engineering, KU Leuven, Leuven 3000, Belgium
| | - Paul H J Kouwer
- Institute for Molecules and Materials, Radboud University, Nijmegen 6525 AJ, The Netherlands
| | - Susana Rocha
- Molecular Imaging and Photonics, Chemistry Department, KU Leuven, Leuven 3000, Belgium
| |
Collapse
|
5
|
Kluivers KB, Lince SL, Ruiz-Zapata AM, Post WM, Cartwright R, Kerkhof MH, Widomska J, De Witte W, Pecanka J, Kiemeney LA, Vermeulen SH, Goeman JJ, Allen-Brady K, Oosterwijk E, Poelmans G. Molecular Landscape of Pelvic Organ Prolapse Provides Insights into Disease Etiology. Int J Mol Sci 2023; 24:ijms24076087. [PMID: 37047060 PMCID: PMC10094264 DOI: 10.3390/ijms24076087] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Revised: 03/07/2023] [Accepted: 03/20/2023] [Indexed: 04/14/2023] Open
Abstract
Pelvic organ prolapse (POP) represents a major health care burden in women, but its underlying pathophysiological mechanisms have not been elucidated. We first used a case-control design to perform an exome chip study in 526 women with POP and 960 control women to identify single nucleotide variants (SNVs) associated with the disease. We then integrated the functional interactions between the POP candidate proteins derived from the exome chip study and other POP candidate molecules into a molecular landscape. We found significant associations between POP and SNVs in 54 genes. The proteins encoded by 26 of these genes fit into the molecular landscape, together with 43 other POP candidate molecules. The POP landscape is located in and around epithelial cells and fibroblasts of the urogenital tract and harbors four interacting biological processes-epithelial-mesenchymal transition, immune response, modulation of the extracellular matrix, and fibroblast function-that are regulated by sex hormones and TGFB1. Our findings were corroborated by enrichment analyses of differential gene expression data from an independent POP cohort. Lastly, based on the landscape and using vaginal fibroblasts from women with POP, we predicted and showed that metformin alters gene expression in these fibroblasts in a beneficial direction. In conclusion, our integrated molecular landscape of POP provides insights into the biological processes underlying the disease and clues towards novel treatments.
Collapse
Affiliation(s)
- Kirsten B Kluivers
- Department of Obstetrics and Gynecology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
| | - Sabrina L Lince
- Department of Obstetrics and Gynecology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
| | - Alejandra M Ruiz-Zapata
- Department of Obstetrics and Gynecology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
| | - Wilke M Post
- Department of Obstetrics and Gynecology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
| | - Rufus Cartwright
- Department of Gynaecology, Chelsea and Westminster NHS Foundation Trust, Department of Epidemiology and Biostatistics, Imperial College London, London SW7 2AZ, UK
| | - Manon H Kerkhof
- Department of Gynaecology and Reconstructive Pelvic Surgery, Curilion Women's Health Clinic, 2015 BJ Haarlem, The Netherlands
| | - Joanna Widomska
- Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, 6525 GD Nijmegen, The Netherlands
| | - Ward De Witte
- Department of Human Genetics, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
| | - Jakub Pecanka
- Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
- Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, 6525 EZ Nijmegen, The Netherlands
| | - Lambertus A Kiemeney
- Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, 6525 EZ Nijmegen, The Netherlands
| | - Sita H Vermeulen
- Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, 6525 EZ Nijmegen, The Netherlands
| | - Jelle J Goeman
- Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
- Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, 6525 EZ Nijmegen, The Netherlands
| | - Kristina Allen-Brady
- Department of Internal Medicine, Genetic Epidemiology, University of Utah, Salt Lake City, UT 84132, USA
| | - Egbert Oosterwijk
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
| | - Geert Poelmans
- Department of Human Genetics, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
| |
Collapse
|
6
|
Oosterwijk E, Kleidendorst S, Konijnenberg M, Merkx R, Twumasi-Boateng K, Chandler P, Wheatcroft M, Heskamp S, Mulders P. Preclinical evaluation of targeted radionuclide therapy combined with immune checkpoint inhibition. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01072-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
7
|
van Puffelen JH, Novakovic B, van Emst L, Kooper D, Zuiverloon TCM, Oldenhof UTH, Witjes JA, Galesloot TE, Vrieling A, Aben KKH, Kiemeney LALM, Oosterwijk E, Netea MG, Boormans JL, van der Heijden AG, Joosten LAB, Vermeulen SH. Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections. J Immunother Cancer 2023; 11:jitc-2022-005518. [PMID: 36693678 PMCID: PMC9884868 DOI: 10.1136/jitc-2022-005518] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/29/2022] [Indexed: 01/26/2023] Open
Abstract
BACKGROUND BCG is recommended as intravesical immunotherapy to reduce the risk of tumor recurrence in patients with non-muscle invasive bladder cancer (NMIBC). Currently, it is unknown whether intravesical BCG application induces trained immunity. METHODS The aim of this research was to determine whether BCG immunotherapy induces trained immunity in NMIBC patients. We conducted a prospective observational cohort study in 17 NMIBC patients scheduled for BCG therapy and measured trained immunity parameters at 9 time points before and during a 1-year BCG maintenance regimen. Ex vivo cytokine production by peripheral blood mononuclear cells, epigenetic modifications, and changes in the monocyte transcriptome were measured. The frequency of respiratory infections was investigated in two larger cohorts of BCG-treated and non-BCG treated NMIBC patients as a surrogate measurement of trained immunity. Gene-based association analysis of genetic variants in candidate trained immunity genes and their association with recurrence-free survival and progression-free survival after BCG therapy was performed to investigate the hypothesized link between trained immunity and clinical response. RESULTS We found that intravesical BCG does induce trained immunity based on an increased production of TNF and IL-1β after heterologous ex vivo stimulation of circulating monocytes 6-12 weeks after intravesical BCG treatment; and a 37% decreased risk (OR 0.63 (95% CI 0.40 to 1.01)) for respiratory infections in BCG-treated versus non-BCG-treated NMIBC patients. An epigenomics approach combining chromatin immuno precipitation-sequencing and RNA-sequencing with in vitro trained immunity experiments identified enhanced inflammasome activity in BCG-treated individuals. Finally, germline variation in genes that affect trained immunity was associated with recurrence and progression after BCG therapy in NMIBC. CONCLUSION We conclude that BCG immunotherapy induces trained immunity in NMIBC patients and this may account for the protective effects against respiratory infections. The data of our gene-based association analysis suggest that a link between trained immunity and oncological outcome may exist. Future studies should further investigate how trained immunity affects the antitumor immune responses in BCG-treated NMIBC patients.
Collapse
Affiliation(s)
- Jelmer H van Puffelen
- Department of Internal Medicine, Radboudumc, Nijmegen, The Netherlands,Department for Health Evidence, Radboudumc, Nijmegen, The Netherlands
| | - Boris Novakovic
- Department of Paediatrics, Murdoch Children's Research Institute, Melbourne, Victoria, Australia
| | - Liesbeth van Emst
- Department of Internal Medicine, Radboudumc, Nijmegen, The Netherlands
| | - Denise Kooper
- Department of Urology, Erasmus MC Cancer Centre, Rotterdam, The Netherlands
| | | | | | - J Alfred Witjes
- Department of Urology, Radboudumc, Nijmegen, The Netherlands
| | | | - Alina Vrieling
- Department for Health Evidence, Radboudumc, Nijmegen, The Netherlands
| | - Katja K H Aben
- Department for Health Evidence, Radboudumc, Nijmegen, The Netherlands,IKNL, Utrecht, The Netherlands
| | | | | | - Mihai G Netea
- Department of Internal Medicine, Radboudumc, Nijmegen, The Netherlands,Department of Immunology and Metabolism, University of Bonn, Life & Medical Sciences Institute, Bonn, Germany
| | - Joost L Boormans
- Department of Urology, Erasmus MC Cancer Centre, Rotterdam, The Netherlands
| | | | - Leo A B Joosten
- Department of Internal Medicine, Radboudumc, Nijmegen, The Netherlands,Department of Medical Genetics, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Sita H Vermeulen
- Department for Health Evidence, Radboudumc, Nijmegen, The Netherlands
| |
Collapse
|
8
|
de Wit RJJ, van Dis DJ, Bertrand ME, Tiemessen D, Siddiqi S, Oosterwijk E, Verhagen AFTM. Scaffold-based tissue engineering: Supercritical carbon dioxide as an alternative method for decellularization and sterilization of dense materials. Acta Biomater 2023; 155:323-332. [PMID: 36423818 DOI: 10.1016/j.actbio.2022.11.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2022] [Revised: 11/14/2022] [Accepted: 11/15/2022] [Indexed: 11/23/2022]
Abstract
Development of ready-to-use biomaterials and scaffolds is vital for further advancement of scaffold-based tissue engineering in clinical practice. Scaffolds need to mimic 3D ultrastructure, have adequate mechanical strength, are biocompatible, non-immunogenic and need to promote tissue regeneration in vivo. Although decellularization of native tissues seems promising to deliver scaffolds that meet these criteria, adequate decellularization of hard, poorly penetrable and poorly diffusible tissues remains challenging whilst being a very time-consuming process. In this study, a method to decellularize hard, dense tissues using supercritical carbon-dioxide preceded by a freeze/thaw cycle and followed by several washing steps is presented, demonstrating decellularisation efficiency and substantially reduced production/handling time. Additionally, supercritical carbon-dioxide treatment was used as sterilization method, further reducing the time required to produce the final scaffold. Histological evaluation showed that, after fine-tuning of the process, a partially acellular scaffold was obtained, with preservation of glycosaminoglycans and collagen fibers, albeit that the amount of residual dsDNA was still higher then chemically decellularized tissue. Biomechanical properties of the scaffold were similar to the native, non-decellularized tissue. After sterilization with supercritical carbon-dioxide the simulated functional outcome was more similar to native trachea, when compared to sterilization using gamma irradiation. Thus, decellularization and sterilization using supercritical carbon-dioxide with washing steps is an effective method for dense cartilaginous materials, and tuneable to meet different demands in other applications, but further optimization may be required. STATEMENT OF SIGNIFICANCE: Further advancement of the use of tissue engineered tracheal constructs is restricted by the lack of the ideal scaffold. Decellularized trachea is considered a promising scaffold, but the hard, poorly diffusible tissue remains challenging while forming a very time consumable process. Decellularization using supercritical carbon dioxide (scCO2) seems promising, resulting in efficient removal of cellular material while reducing production and handling time. Addition of scCO2 as a sterilization method resulted in further time reduction while improving functional outcome in comparison with traditional sterilization methods. This study presents an promising alternative method for decellularization and sterilization of dense materials, which can be tuned to meet different demands in other applications.
Collapse
Affiliation(s)
- R J J de Wit
- Department of Cardio-Thoracic Surgery, Radboud University Medical Center, Geert Grooteplein 28, GE, Nijmegen 6525, the Netherlands.
| | - D J van Dis
- Department of Urology, Radboud Institute for Molecular Life Science, Radboud University Medical Center, Geert Grooteplein 28, GE, Nijmegen 6525, the Netherlands
| | - M E Bertrand
- HCM Medical, Kerkenbos 10-113, BJ, Nijmegen 6546, The Netherlands
| | - D Tiemessen
- Department of Urology, Radboud Institute for Molecular Life Science, Radboud University Medical Center, Geert Grooteplein 28, GE, Nijmegen 6525, the Netherlands
| | - S Siddiqi
- Department of Cardio-Thoracic Surgery, Radboud University Medical Center, Geert Grooteplein 28, GE, Nijmegen 6525, the Netherlands
| | - E Oosterwijk
- Department of Urology, Radboud Institute for Molecular Life Science, Radboud University Medical Center, Geert Grooteplein 28, GE, Nijmegen 6525, the Netherlands
| | - A F T M Verhagen
- Department of Cardio-Thoracic Surgery, Radboud University Medical Center, Geert Grooteplein 28, GE, Nijmegen 6525, the Netherlands
| |
Collapse
|
9
|
Maurits JS, van der Zanden LF, Diekstra MH, Ambert V, Castellano D, Garcia-Donas J, Troyas RG, Guchelaar HJ, Jaehde U, Junker K, Martinez-Cardus A, Radu MT, Rodriguez-Antona C, Roessler M, Warren A, Eisen T, Oosterwijk E, Kiemeney LA, Vermeulen SH. Logical Imputation to Optimize Prognostic Risk Classification in Metastatic Renal Cell Cancer. KCA 2022. [DOI: 10.3233/kca-220007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND: Application of the MSKCC and IMDC models is recommended for prognostication in metastatic renal cell cancer (mRCC). Patient classification in MSKCC and IMDC risk groups in real-world observational studies is often hampered by missing data on required pre-treatment characteristics. OBJECTIVE: To evaluate the effect of application of easy-to-use logical, or deductive, imputation on MSKCC and IMDC risk classification in an observational study setting. PATIENTS AND METHODS: We used data on 713 mRCC patients with first-line sunitinib treatment from our observational European multi-centre study EuroTARGET. Pre-treatment characteristics and follow-up were derived from medical files. Hospital-specific cut-off values for laboratory measurements were requested. The effect of logical imputation of missing data and consensus versus hospital-specific cut-off values on patient classification and the subsequent models’ predictive performance for progression-free and overall survival (OS) was evaluated. RESULTS: 45% of the patients had missing data for≥1 pre-treatment characteristic for either model. Still, 72% of all patients could be unambiguously classified using logical imputation. Use of consensus instead of hospital-specific cut-offs led to a shift in risk group for 12% and 7% of patients for the MSKCC and IMDC model, respectively. Using logical imputation or other cut-offs did not influence the models’ predictive performance. These were in line with previous reports (c-statistic ∼0.64 for OS) CONCLUSIONS: Logical imputation leads to a substantial increase in the proportion of patients that can be correctly classified into poor and intermediate MSKCC and IMDC risk groups in observational studies and its use in the field should be advocated.
Collapse
Affiliation(s)
| | | | - Meta H.M. Diekstra
- Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands
- Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - Valentin Ambert
- University of Medicine and Pharmacy Carol Davila, Bucuresti, Romania
| | - Daniel Castellano
- Medical Oncology Department, Hospital Universitario 12 de Octubre, + 12 Research Institute, (CiberOnc), Madrid, Spain
| | - Jesus Garcia-Donas
- Medical Oncology, HM Hospitales-Centro Integral Oncológico HM Clara Campal, Madrid, Spain
| | | | - Henk-Jan Guchelaar
- Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands
| | - Ulrich Jaehde
- Institute of Pharmacy, Department of Clinical Pharmacy, University of Bonn, Bonn, Germany
| | - Kerstin Junker
- Clinic of Urology and Paediatric Urology, Saarland University, Homburg, Germany
- Department of Urology, Jena University Hospital, Jena, Germany
| | - Anna Martinez-Cardus
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Catalonia, Spain
- Institut Catala d’Oncologia (ICO), Badalona Applied Research Group in Oncology (B-ARGO Group), Institut Investigació Germans Trias i Pujol (IGTP), Badalona, Spain
| | - Marius T. Radu
- University of Medicine and Pharmacy Carol Davila, Bucuresti, Romania
- Spitalul Clinic de Nefrologie “Dr. Carol Davila”, Bucuresti, Romania
| | - Cristina Rodriguez-Antona
- Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO) and Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain
| | - Max Roessler
- CESAR Central Office, CESAR Central European Society for Anticancer Drug Research-EWIV, Vienna, Austria
| | - Anne Warren
- Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK
| | - Tim Eisen
- Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK
| | - Egbert Oosterwijk
- Radboud University Medical Center, Nijmegen, The Netherlands
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Catalonia, Spain
| | - Lambertus A.L.M. Kiemeney
- Radboud University Medical Center, Nijmegen, The Netherlands
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Catalonia, Spain
| | | |
Collapse
|
10
|
Kleinendorst SC, Oosterwijk E, Bussink J, Westdorp H, Konijnenberg MW, Heskamp S. Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment. Clin Cancer Res 2022; 28:3652-3657. [PMID: 35471557 PMCID: PMC9433955 DOI: 10.1158/1078-0432.ccr-21-4332] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Revised: 02/03/2022] [Accepted: 04/11/2022] [Indexed: 01/07/2023]
Abstract
The development of immunotherapy, in particular immune checkpoint inhibitors (ICI), has revolutionized cancer treatment in the past decades. However, its efficacy is still limited to subgroups of patients with cancer. Therefore, effective treatment combination strategies are needed. Here, radiotherapy is highly promising, as it can induce immunogenic cell death, triggering the release of pro-inflammatory cytokines, thereby creating an immunogenic phenotype and sensitizing tumors to ICI. Recently, targeted radionuclide therapy (TRT) has attained significant interest for cancer treatment. In this approach, a tumor-targeting radiopharmaceutical is used to specifically deliver a therapeutic radiation dose to all tumor cells, including distant metastatic lesions, while limiting radiation exposure to healthy tissue. However, fundamental differences between TRT and conventional radiotherapy make it impossible to directly extrapolate the biological effects from conventional radiotherapy to TRT. In this review, we present a comprehensive overview of studies investigating the immunomodulatory effects of TRT and the efficacy of combined TRT-ICI treatment. Preclinical studies have evaluated a variety of murine cancer models in which α- or β-emitting radionuclides were directed to a diverse set of targets. In addition, clinical trials are ongoing to assess safety and efficacy of combined TRT-ICI in patients with cancer. Taken together, research indicates that combining TRT and ICI might improve therapeutic response in patients with cancer. Future research has to disclose what the optimal conditions are in terms of dose and treatment schedule to maximize the efficacy of this combined approach.
Collapse
Affiliation(s)
- Simone C. Kleinendorst
- Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands
| | - Egbert Oosterwijk
- Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands
| | - Johan Bussink
- Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Harm Westdorp
- Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.,Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Mark W. Konijnenberg
- Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands
| | - Sandra Heskamp
- Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.,Corresponding Author: Sandra Heskamp, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, the Netherlands. Phone: 243-614-511; E-mail:
| |
Collapse
|
11
|
Oosterwijk-Wakka JC, de Weijert MCA, Franssen GM, Kolev DR, de Haan TAFJ, Boerman OC, Mulders PFA, Oosterwijk E. Combination of sunitinib and 177Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer. Neoplasia 2022; 32:100826. [PMID: 35878454 PMCID: PMC9309230 DOI: 10.1016/j.neo.2022.100826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Accepted: 07/11/2022] [Indexed: 11/25/2022]
Abstract
Sunitinib is an effective treatment for patients with metastatic Renal Cell Carcinoma (mRCC) but ultimately resistance occurs. The aim of this study was to investigate sunitinib resistance in RCCs and to develop therapeutic combination strategies with targeted radioimmunotherapy (RIT). We studied two RCC models, analyzed Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) and AXL/MET expression and performed therapy studies in Balb/cnu/nu mice combining sunitinib and [177Lu]Lu-cG250 RIT (6.5 MBq/10 μg), specifically targeting RCC cells. pAXL and pMET were expressed in sunitinib-resistant SK-RC-52 and absent in sunitinib-sensitive NU12. NGS evaluation showed that expression of VEGFA, VEGFB, VEGFD, PGF and VEGFR1,2,3 was higher and expression of VEGFC and PDGFA was lower in NU12 than in SK-RC-52. Therapy studies combining sunitinib with [177Lu]Lu-cG250 RIT showed that the best response in mice with “resistant” SK-RC-52 tumors was observed with two cycles of Sunitinib and [177Lu]Lu-cG250 RIT, probably due to increased vascular permeability by sunitinib treatment. In the “sensitive” NU12 model, two cycles of [177Lu]Lu-cG250 RIT and two cycles of combination treatment were equally effective. Enhanced therapeutic efficacy was achieved when two agents ([177Lu]Lu-cG250 RIT and sunitinib) that on their own did not induce satisfactory response levels, are combined. Our findings provide a promising new therapeutic strategy for patients with advanced RCC.
Collapse
Affiliation(s)
- Jeannette C Oosterwijk-Wakka
- Radboud university medical center, Department of Urology, 267 Experimental Urology, PO Box 9101, 6500 HB Nijmegen, the Netherlands.
| | - Mirjam C A de Weijert
- Radboud university medical center, Department of Urology, 267 Experimental Urology, PO Box 9101, 6500 HB Nijmegen, the Netherlands
| | - Gerben M Franssen
- Radboud university medical center, Department of Radiology and Nuclear Medicine, PO Box 9101, 6500 HB Nijmegen, the Netherlands
| | - Dimitar R Kolev
- Radboud university medical center, Department for Health Evidence, PO Box 9101, 6500 HB Nijmegen, the Netherlands
| | - Ton A F J de Haan
- Radboud university medical center, Department for Health Evidence, PO Box 9101, 6500 HB Nijmegen, the Netherlands
| | - Otto C Boerman
- Radboud university medical center, Animal research facility, PO Box 9101, 6500 HB Nijmegen, the Netherlands
| | - Peter F A Mulders
- Radboud university medical center, Department of Urology, PO Box 9101, 6500 HB Nijmegen, the Netherlands
| | - Egbert Oosterwijk
- Radboud university medical center, Department of Urology, 267 Experimental Urology, PO Box 9101, 6500 HB Nijmegen, the Netherlands
| |
Collapse
|
12
|
Zhang Z, Chen W, Tiemessen DM, Oosterwijk E, Kouwer PHJ. A Temperature-Based Easy-Separable (TempEasy) 3D Hydrogel Coculture System. Adv Healthc Mater 2022; 11:e2102389. [PMID: 35029325 DOI: 10.1002/adhm.202102389] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Revised: 12/10/2021] [Indexed: 12/13/2022]
Abstract
Interactions between different cell types are crucial for their behavior in tissues, but are rarely considered in 3D in vitro cell culture experiments. One reason is that such coculture experiments are sometimes difficult to perform in 3D or require specialized equipment or know-how. Here, a new 3D cell coculture system is introduced, TempEasy, which is readily applied in any cell culture lab. The matrix material is based on polyisocyanide hydrogels, which closely resemble the mechanical characteristics of the natural extracellular matrix. Gels with different gelation temperatures, seeded with different cells, are placed on top of each other to form an indirect coculture. Cooling reverses gelation, allowing cell harvesting from each layer separately, which benefits downstream analysis. To demonstrate the potential of TempEasy , human adipose stem cells (hADSCs) with vaginal epithelial fibroblasts are cocultured. The analysis of a 7-day coculture shows that hADSCs promote cell-cell interaction of fibroblasts, while fibroblasts promote proliferation and differentiation of hADSCs. TempEasy provides a straightforward operational platform for indirect cocultures of cells of different lineages in well-defined microenvironments.
Collapse
Affiliation(s)
- Zhaobao Zhang
- Institute for Molecules and Materials Radboud University Nijmegen Heyendaalseweg 135 Nijmegen 6525 AJ The Netherlands
| | - Wen Chen
- Institute for Molecules and Materials Radboud University Nijmegen Heyendaalseweg 135 Nijmegen 6525 AJ The Netherlands
| | - Dorien M. Tiemessen
- Department of Urology Radboud Institute for Molecular Life Sciences Radboud University Medical Center Geert Grooteplein Zuid 28 Nijmegen 6525 GA The Netherlands
| | - Egbert Oosterwijk
- Department of Urology Radboud Institute for Molecular Life Sciences Radboud University Medical Center Geert Grooteplein Zuid 28 Nijmegen 6525 GA The Netherlands
| | - Paul H. J. Kouwer
- Institute for Molecules and Materials Radboud University Nijmegen Heyendaalseweg 135 Nijmegen 6525 AJ The Netherlands
| |
Collapse
|
13
|
Roussel E, Capitanio U, Kutikov A, Oosterwijk E, Pedrosa I, Rowe SP, Gorin MA. Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review. Eur Urol 2022; 81:476-488. [PMID: 35216855 PMCID: PMC9844544 DOI: 10.1016/j.eururo.2022.01.040] [Citation(s) in RCA: 40] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Revised: 01/08/2022] [Accepted: 01/21/2022] [Indexed: 01/19/2023]
Abstract
CONTEXT The incidental detection of localized renal masses has been rising steadily, but a significant proportion of these tumors are benign or indolent and, in most cases, do not require treatment. At the present time, a majority of patients with an incidentally detected renal tumor undergo treatment for the presumption of cancer, leading to a significant number of unnecessary surgical interventions that can result in complications including loss of renal function. Thus, there exists a clinical need for improved tools to aid in the pretreatment characterization of renal tumors to inform patient management. OBJECTIVE To systematically review the evidence on noninvasive, imaging-based tools for solid renal mass characterization. EVIDENCE ACQUISITION The MEDLINE database was systematically searched for relevant studies on novel imaging techniques and interpretative tools for the characterization of solid renal masses, published in the past 10 yr. EVIDENCE SYNTHESIS Over the past decade, several novel imaging tools have offered promise for the improved characterization of indeterminate renal masses. Technologies of particular note include multiparametric magnetic resonance imaging of the kidney, molecular imaging with targeted radiopharmaceutical agents, and use of radiomics as well as artificial intelligence to enhance the interpretation of imaging studies. Among these, 99mTc-sestamibi single photon emission computed tomography/computed tomography (CT) for the identification of benign renal oncocytomas and hybrid oncocytic chromophobe tumors, and positron emission tomography/CT imaging with radiolabeled girentuximab for the identification of clear cell renal cell carcinoma, are likely to be closest to implementation in clinical practice. CONCLUSIONS A number of novel imaging tools stand poised to aid in the noninvasive characterization of indeterminate renal masses. In the future, these tools may aid in patient management by providing a comprehensive virtual biopsy, complete with information on tumor histology, underlying molecular abnormalities, and ultimately disease prognosis. PATIENT SUMMARY Not all renal tumors require treatment, as a significant proportion are either benign or have limited metastatic potential. Several innovative imaging tools have shown promise for their ability to improve the characterization of renal tumors and provide guidance in terms of patient management.
Collapse
Affiliation(s)
- Eduard Roussel
- Department of Urology, University Hospitals Leuven, Leuven, Belgium
| | - Umberto Capitanio
- Department of Urology, University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Alexander Kutikov
- Division of Urology, Department of Surgery, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA
| | - Egbert Oosterwijk
- Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences (RIMLS), Nijmegen, The Netherlands
| | - Ivan Pedrosa
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Advanced Imaging Research Center. University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Steven P Rowe
- The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Michael A Gorin
- Urology Associates and UPMC Western Maryland, Cumberland, MD, USA; Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
| |
Collapse
|
14
|
Celikkin N, Mastrogiacomo S, Dou W, Heerschap A, Oosterwijk E, Walboomers XF, Święszkowski W. In vitro and in vivo assessment of a 3D printable gelatin methacrylate hydrogel for bone regeneration applications. J Biomed Mater Res B Appl Biomater 2022; 110:2133-2145. [PMID: 35388573 DOI: 10.1002/jbm.b.35067] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Revised: 03/11/2022] [Accepted: 03/19/2022] [Indexed: 12/15/2022]
Abstract
Bone tissue engineering (BTE) has made significant progress in developing and assessing different types of bio-substitutes. However, scaffolds production through standardized methods, as required for good manufacturing process (GMP), and post-transplant in vivo monitoring still limit their translation into the clinic. 3D printed 5% GelMA scaffolds have been prepared through an optimized and reproducible process in this work. Mesenchymal stem cells (MSC) were encapsulated in the 3D printable GelMA ink, and their biological properties were assessed in vitro to evaluate their potential for cell delivery application. Moreover, in vivo implantation of the pristine 3D printed GelMA has been performed in a rat condyle defect model. Whereas optimal tissue integration was observed via histology, no signs of fibrotic encapsulation or inhibited bone formation were attained. A multimodal imaging workflow based on computed tomography (CT) and magnetic resonance imaging (MRI) allowed the simultaneous monitoring of both new bone formation and scaffold degradation. These outcomes point out the direction to undertake in developing 3D printed-based hydrogels for BTE that can allow a faster transition into clinical use.
Collapse
Affiliation(s)
- Nehar Celikkin
- Faculty of Material Science and Engineering, Warsaw University of Technology, Warsaw, Poland.,Institute of Physical Chemistry, Polish Academy of Sciences, Warsaw, Poland
| | - Simone Mastrogiacomo
- Department of Biomaterials, Radboud University Medical Center, Nijmegen, The Netherlands.,Laboratory of Functional and Molecular Imaging, NINDS, National Institutes of Health, Bethesda, MD, USA
| | - Weiqiang Dou
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Arend Heerschap
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Egbert Oosterwijk
- Department of Urology, Radboud Institute for Molecular Life Science, Radboud University Medical Center, Nijmegen, The Netherlands
| | - X Frank Walboomers
- Department of Biomaterials, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Wojciech Święszkowski
- Faculty of Material Science and Engineering, Warsaw University of Technology, Warsaw, Poland
| |
Collapse
|
15
|
Post WM, Widomska J, Grens H, Coenen MJH, Martens FMJ, Janssen DAW, IntHout J, Poelmans G, Oosterwijk E, Kluivers KB. Molecular Processes in Stress Urinary Incontinence: A Systematic Review of Human and Animal Studies. Int J Mol Sci 2022; 23:ijms23063401. [PMID: 35328824 PMCID: PMC8949972 DOI: 10.3390/ijms23063401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Revised: 03/10/2022] [Accepted: 03/18/2022] [Indexed: 02/01/2023] Open
Abstract
Stress urinary incontinence (SUI) is a common and burdensome condition. Because of the large knowledge gap around the molecular processes involved in its pathophysiology, the aim of this review was to provide a systematic overview of genetic variants, gene and protein expression changes related to SUI in human and animal studies. On 5 January 2021, a systematic search was performed in Pubmed, Embase, Web of Science, and the Cochrane library. The screening process and quality assessment were performed in duplicate, using predefined inclusion criteria and different quality assessment tools for human and animal studies respectively. The extracted data were grouped in themes per outcome measure, according to their functions in cellular processes, and synthesized in a narrative review. Finally, 107 studies were included, of which 35 used animal models (rats and mice). Resulting from the most examined processes, the evidence suggests that SUI is associated with altered extracellular matrix metabolism, estrogen receptors, oxidative stress, apoptosis, inflammation, neurodegenerative processes, and muscle cell differentiation and contractility. Due to heterogeneity in the studies (e.g., in examined tissues), the precise contribution of the associated genes and proteins in relation to SUI pathophysiology remained unclear. Future research should focus on possible contributors to these alterations.
Collapse
Affiliation(s)
- Wilke M. Post
- Department of Obstetrics and Gynecology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; (W.M.P.); (H.G.)
| | - Joanna Widomska
- Department of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; (J.W.); (G.P.)
| | - Hilde Grens
- Department of Obstetrics and Gynecology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; (W.M.P.); (H.G.)
| | - Marieke J. H. Coenen
- Radboud Institute of Health Sciences, Department of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands;
| | - Frank M. J. Martens
- Department of Urology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; (F.M.J.M.); (D.A.W.J.); (E.O.)
| | - Dick A. W. Janssen
- Department of Urology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; (F.M.J.M.); (D.A.W.J.); (E.O.)
| | - Joanna IntHout
- Department of Health Evidence, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands;
| | - Geert Poelmans
- Department of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; (J.W.); (G.P.)
| | - Egbert Oosterwijk
- Department of Urology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; (F.M.J.M.); (D.A.W.J.); (E.O.)
| | - Kirsten B. Kluivers
- Department of Obstetrics and Gynecology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; (W.M.P.); (H.G.)
- Correspondence:
| |
Collapse
|
16
|
Oosterwijk-Wakka J, Xu J, De Weijert M, Kenyon A, De Jonge P, Dolstra H, Mulders P, Oosterwijk E. CAIX-specific CAR-NK targeting renal cell carcinoma. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)01191-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
17
|
Merkx R, Hekman M, Oosterwijk E, Muselaers C, Langenhuijsen J, Rijpkema M, Mulders P. Intraoperative dual-modality imaging in clear cell renal cell carcinoma. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00430-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
18
|
Palacio-Castañeda V, Oude Egberink R, Sait A, Andrée L, Sala BM, Hassani Besheli N, Oosterwijk E, Nilvebrant J, Leeuwenburgh SCG, Brock R, Verdurmen WPR. Mimicking the Biology of Engineered Protein and mRNA Nanoparticle Delivery Using a Versatile Microfluidic Platform. Pharmaceutics 2021; 13:pharmaceutics13111944. [PMID: 34834361 PMCID: PMC8624409 DOI: 10.3390/pharmaceutics13111944] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Revised: 11/08/2021] [Accepted: 11/12/2021] [Indexed: 12/24/2022] Open
Abstract
To investigate the delivery of next-generation macromolecular drugs, such as engineered proteins and mRNA-containing nanoparticles, there is an increasing push towards the use of physiologically relevant disease models that incorporate human cells and do not face ethical dilemmas associated with animal use. Here, we illustrate the versatility and ease of use of a microfluidic platform for studying drug delivery using high-resolution microscopy in 3D. Using this microfluidic platform, we successfully demonstrate the specific targeting of carbonic anhydrase IX (CAIX) on cells overexpressing the protein in a tumor-mimicking chip system using affibodies, with CAIX-negative cells and non-binding affibodies as controls. Furthermore, we demonstrate this system’s feasibility for testing mRNA-containing biomaterials designed to regenerate bone defects. To this end, peptide- and lipid-based mRNA formulations were successfully mixed with colloidal gelatin in microfluidic devices, while translational activity was studied by the expression of a green fluorescent protein. This microfluidic platform enables the testing of mRNA delivery from colloidal biomaterials of relatively high densities, which represents a first important step towards a bone-on-a-chip platform. Collectively, by illustrating the ease of adaptation of our microfluidic platform towards use in distinct applications, we show that our microfluidic chip represents a powerful and flexible way to investigate drug delivery in 3D disease-mimicking culture systems that recapitulate key parameters associated with in vivo drug application.
Collapse
Affiliation(s)
- Valentina Palacio-Castañeda
- Department of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands; (V.P.-C.); (R.O.E.); (A.S.)
| | - Rik Oude Egberink
- Department of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands; (V.P.-C.); (R.O.E.); (A.S.)
| | - Arbaaz Sait
- Department of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands; (V.P.-C.); (R.O.E.); (A.S.)
| | - Lea Andrée
- Department of Dentistry—Regenerative Biomaterials, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Philips van Leydenlaan 25, 6525 EX Nijmegen, The Netherlands; (L.A.); (N.H.B.); (S.C.G.L.)
| | - Benedetta Maria Sala
- Division of Protein Engineering, Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, AlbaNova University Center, Royal Institute of Technology, SE-100 44 Stockholm, Sweden; (B.M.S.); (J.N.)
| | - Negar Hassani Besheli
- Department of Dentistry—Regenerative Biomaterials, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Philips van Leydenlaan 25, 6525 EX Nijmegen, The Netherlands; (L.A.); (N.H.B.); (S.C.G.L.)
| | - Egbert Oosterwijk
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 26/28, 6525 GA Nijmegen, The Netherlands;
| | - Johan Nilvebrant
- Division of Protein Engineering, Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, AlbaNova University Center, Royal Institute of Technology, SE-100 44 Stockholm, Sweden; (B.M.S.); (J.N.)
| | - Sander C. G. Leeuwenburgh
- Department of Dentistry—Regenerative Biomaterials, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Philips van Leydenlaan 25, 6525 EX Nijmegen, The Netherlands; (L.A.); (N.H.B.); (S.C.G.L.)
| | - Roland Brock
- Department of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands; (V.P.-C.); (R.O.E.); (A.S.)
- Department of Medical Biochemistry, College of Medicine and Medical Sciences, Arabian Gulf University, Manama 329, Bahrain
- Correspondence: (R.B.); (W.P.R.V.)
| | - Wouter P. R. Verdurmen
- Department of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands; (V.P.-C.); (R.O.E.); (A.S.)
- Correspondence: (R.B.); (W.P.R.V.)
| |
Collapse
|
19
|
de Wit R, Siddiqi S, Tiemessen D, Snabel R, Veenstra GJ, Oosterwijk E, Verhagen A. Isolation of multipotent progenitor cells from pleura and pericardium for tracheal tissue engineering purposes. J Cell Mol Med 2021; 25:10869-10878. [PMID: 34725901 PMCID: PMC8642678 DOI: 10.1111/jcmm.16916] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Revised: 08/09/2021] [Accepted: 08/17/2021] [Indexed: 12/12/2022] Open
Abstract
Tissue engineering (TE) of long tracheal segments is conceptually appealing for patients with inoperable tracheal pathology. In tracheal TE, stem cells isolated from bone marrow or adipose tissue have been employed, but the ideal cell source has yet to be determined. When considering the origin of stem cells, cells isolated from a source embryonically related to the trachea may be more similar. In this study, we investigated the feasibility of isolating progenitor cells from pleura and pericard as an alternative cells source for tracheal tissue engineering. Porcine progenitor cells were isolated from pleura, pericard, trachea and adipose tissue and expanded in culture. Isolated cells were characterized by PCR, RNA sequencing, differentiation assays and cell survival assays and were compared to trachea and adipose‐derived progenitor cells. Progenitor‐like cells were successfully isolated and expanded from pericard and pleura as indicated by gene expression and functional analyses. Gene expression analysis and RNA sequencing showed a stem cell signature indicating multipotency, albeit that subtle differences between different cell sources were visible. Functional analysis revealed that these cells were able to differentiate towards chondrogenic, osteogenic and adipogenic lineages. Isolation of progenitor cells from pericard and pleura with stem cell features is feasible. Although functional differences with adipose‐derived stem cells were limited, based on their gene expression, pericard‐ and pleura‐derived stem cells may represent a superior autologous cell source for cell seeding in tracheal tissue engineering.
Collapse
Affiliation(s)
- Rayna de Wit
- Department of Cardio-thoracic surgery, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Sailay Siddiqi
- Department of Cardio-thoracic surgery, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Dorien Tiemessen
- Department of Urology, Radboud Institute for Molecular Life Science, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Rebecca Snabel
- Department of Molecular Developmental Biology, Radboud Institute for Molecular Life Science, Faculty of Science, Radboud University, Nijmegen, the Netherlands
| | - Gert Jan Veenstra
- Department of Molecular Developmental Biology, Radboud Institute for Molecular Life Science, Faculty of Science, Radboud University, Nijmegen, the Netherlands
| | - Egbert Oosterwijk
- Department of Urology, Radboud Institute for Molecular Life Science, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Ad Verhagen
- Department of Cardio-thoracic surgery, Radboud University Medical Center, Nijmegen, the Netherlands
| |
Collapse
|
20
|
Brummelhuis ISG, Simons M, Lindner LH, Kort S, de Jong S, Hossann M, Witjes JA, Oosterwijk E. DPPG 2-based thermosensitive liposomes as drug delivery system for effective muscle-invasive bladder cancer treatment in vivo. Int J Hyperthermia 2021; 38:1415-1424. [PMID: 34581259 DOI: 10.1080/02656736.2021.1983038] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
PURPOSE Recommended treatments for muscle-invasive bladder cancer (MIBC) come with considerable morbidity. Hyperthermia (HT) triggered drug release from phosphatidylglycerol-based thermosensitive liposomes (DPPG2-TSL) might prevent surgical bladder removal and toxicity from systemic chemotherapy. We aimed to assess the efficacy of DPPG2-TSL with HT in a syngeneic orthotopic rat urothelial carcinoma model. METHODS A total of 191 female Fischer F344 rats were used. Bladder tumors were initiated by inoculation of AY-27 cells and tumor-bearing rats were selected with cystoscopy and semi-randomized over treatment groups. On days 5 and 8, animals were treated with DOX in different treatment modalities: intravenous (iv) DPPG2-TSL-DOX with HT, iv free DOX without HT, intravesical DOX without HT, intravesical DOX with HT or no treatment (control group), respectively. Animals were euthanized on day 14 and complete tumor response was assessed by histopathological evaluation. RESULTS Iv DPPG2-TSL-DOX + HT resulted in a favorable rate of animals with complete tumor response (70%), compared to iv free DOX (18%, p = .02), no treatment (0%, p = .001), and intravesical DOX with (43%, p = .35) or without HT (50%, p = .41). All rats receiving intravesical DOX with HT and 24% of rats treated with DPPG2-TSL-DOX containing the same DOX dose with HT had to be euthanized before day 14 because of substantial bodyweight loss, which was associated with dilated ureters urine retention in a few rats. CONCLUSION Treatment with DPPG2-TSL-DOX combined with intravesical HT outperformed systemic and intravesical DOX in vivo. There might be a role for DPPG2-TSL encapsulating chemotherapeutics in the treatment of MIBC in the future.
Collapse
Affiliation(s)
- Iris S G Brummelhuis
- Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Michiel Simons
- Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Lars H Lindner
- Department of Medicine III, University Hospital LMU Munich, Munich, Germany
| | - Simone Kort
- Department of Medicine III, University Hospital LMU Munich, Munich, Germany
| | - Sytse de Jong
- Department of Cardiothoracic Surgery, Radboud University Medical Center, Nijmegen, The Netherlands
| | | | - J Alfred Witjes
- Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Egbert Oosterwijk
- Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
| |
Collapse
|
21
|
Diekstra M, Swen J, van der Zanden L, Vermeulen S, Boven E, Mathijssen R, Oskarsdottir A, Oosterwijk E, Cambon-Thomsen A, Castellano D, Fritsch A, Garcia-Donas J, Rodriguez-Antona C, Jaehde U, Rafnar T, Stefansson K, Bohringer S, Kubo M, Kiemeney L, Guchelaar HJ. 685P Genome-wide association meta-analysis identifies novel variants that correlate with efficacy outcomes in sunitinib-treated patients with metastatic renal cell carcinoma. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
22
|
Merkx RIJ, Lobeek D, Konijnenberg M, Jiménez-Franco LD, Kluge A, Oosterwijk E, Mulders PFA, Rijpkema M. Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma. Eur J Nucl Med Mol Imaging 2021; 48:3277-3285. [PMID: 33651116 PMCID: PMC8426244 DOI: 10.1007/s00259-021-05271-w] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2020] [Accepted: 02/17/2021] [Indexed: 01/20/2023]
Abstract
PURPOSE In this phase I study, we evaluated the safety, biodistribution and dosimetry of [89Zr]Zr-DFO-girentuximab (89Zr-girentuximab) PET/CT imaging in patients with suspicion of clear cell renal cell carcinoma (ccRCC). METHODS Ten eligible patients received an intravenous administration of 37 MBq (± 10%) of 89Zr-girentuximab at mass doses of 5 mg or 10 mg. Safety was evaluated according to the NCI CTCAE (version 4.03). Biodistribution and normal organ dosimetry was performed based on PET/CT images acquired at 0.5, 4, 24, 72 and 168 h post-administration. Additionally, tumour dosimetry was performed in patients with confirmed ccRCC and visible tumour uptake on PET/CT imaging. RESULTS 89Zr-girentuximab was administered in ten patients as per protocol. No treatment-related adverse events ≥ grade 3 were reported. 89Zr-girentuximab imaging allowed successful differentiation between ccRCC and non-ccRCC lesions in all patients, as confirmed with histological data. Dosimetry analysis using OLINDA/EXM 2.1 showed that the organs receiving the highest doses (mean ± SD) were the liver (1.86 ± 0.40 mGy/MBq), the kidneys (1.50 ± 0.22 mGy/MBq) and the heart wall (1.45 ± 0.19 mGy/MBq), with a mean whole body effective dose of 0.57 ± 0.08 mSv/MBq. Tumour dosimetry was performed in the 6 patients with histologically confirmed ccRCC resulting in a median tumour-absorbed dose of 4.03 mGy/MBq (range 1.90-11.6 mGy/MBq). CONCLUSIONS This study demonstrates that 89Zr-girentuximab is safe and well tolerated for the administered activities and mass doses and allows quantitative assessment of 89Zr-girentuximab PET/CT imaging in patients with suspicion of ccRCC. TRIAL REGISTRATION NCT03556046-14th of June, 2018.
Collapse
Affiliation(s)
- Robin I J Merkx
- Department of Medical Imaging: Nuclear Medicine, Radboudumc, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands. .,Department of Urology, Radboudumc, Nijmegen, The Netherlands.
| | - Daphne Lobeek
- Department of Medical Imaging: Nuclear Medicine, Radboudumc, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands
| | - Mark Konijnenberg
- Department of Medical Imaging: Nuclear Medicine, Radboudumc, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands
| | | | - Andreas Kluge
- ABX-CRO advanced pharmaceutical services, Dresden, Germany
| | | | | | - Mark Rijpkema
- Department of Medical Imaging: Nuclear Medicine, Radboudumc, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands
| |
Collapse
|
23
|
Mourits VP, van Puffelen JH, Novakovic B, Bruno M, Ferreira AV, Arts RJ, Groh L, Crișan TO, Zwaag J, Jentho E, Kox M, Pickkers P, van de Veerdonk FL, Weis S, Oosterwijk E, Vermeulen SH, Netea MG, Joosten LA. Lysine methyltransferase G9a is an important modulator of trained immunity. Clin Transl Immunology 2021; 10:e1253. [PMID: 33708384 PMCID: PMC7890679 DOI: 10.1002/cti2.1253] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Revised: 12/22/2020] [Accepted: 01/22/2021] [Indexed: 12/25/2022] Open
Abstract
Objectives Histone methyltransferase G9a, also known as Euchromatic Histone Lysine Methyltransferase 2 (EHMT2), mediates H3K9 methylation which is associated with transcriptional repression. It possesses immunomodulatory effects and is overexpressed in multiple types of cancer. In this study, we investigated the role of G9a in the induction of trained immunity, a de facto innate immune memory, and its effects in non‐muscle‐invasive bladder cancer (NMIBC) patients treated with intravesical Bacillus Calmette‐Guérin (BCG). Methods EHMT2 expression was assessed upon induction of trained immunity by RNA sequencing and Western blotting. G9a inhibitor BIX‐01294 was used to investigate the effect on trained immunity responses in vitro. Subsequent cytokine production was measured by ELISA, epigenetic modifications were measured by ChIP‐qPCR, Seahorse technology was used to measure metabolic changes, and a luminescence assay was used to measure ROS release. RNA sequencing was performed on BIX‐01294‐treated monocytes ex vivo. Results The expression of EHMT2 mRNA and protein decreased in monocytes during induction of trained immunity. G9a inhibition by BIX‐01294 induced trained immunity and amplified trained immunity responses evoked by various microbial ligands in vitro. This was accompanied by decreased H3K9me2 at the promoters of pro‐inflammatory genes. G9a inhibition was also associated with amplified ex vivo trained immunity responses in circulating monocytes of NMIBC patients. Additionally, altered RNA expression of inflammatory genes in monocytes of NMIBC patients was observed upon ex vivo G9a inhibition. Furthermore, intravesical BCG therapy decreased H3K9me2 at the promoter of pro‐inflammatory genes. Conclusion Inhibition of G9a is important in the induction of trained immunity, and G9a may represent a novel therapeutic target in NMIBC patients.
Collapse
Affiliation(s)
- Vera P Mourits
- Department of Internal Medicine Radboud Center for Infectious Diseases (RCI) Radboud University Medical Center Nijmegen The Netherlands
| | - Jelmer H van Puffelen
- Department of Internal Medicine Radboud Center for Infectious Diseases (RCI) Radboud University Medical Center Nijmegen The Netherlands.,Department for Health Evidence Radboud University Medical Center Nijmegen The Netherlands
| | - Boris Novakovic
- Epigenetics Research Murdoch Children's Research Institute Parkville VIC Australia.,Department of Paediatrics University of Melbourne Melbourne VIC Australia
| | - Mariolina Bruno
- Department of Internal Medicine Radboud Center for Infectious Diseases (RCI) Radboud University Medical Center Nijmegen The Netherlands
| | - Anaísa V Ferreira
- Department of Internal Medicine Radboud Center for Infectious Diseases (RCI) Radboud University Medical Center Nijmegen The Netherlands.,Instituto de Ciências Biomédicas Abel Salazar (ICBAS) Universidade do Porto Porto Portugal
| | - Rob Jw Arts
- Department of Internal Medicine Radboud Center for Infectious Diseases (RCI) Radboud University Medical Center Nijmegen The Netherlands
| | - Laszlo Groh
- Department of Internal Medicine Radboud Center for Infectious Diseases (RCI) Radboud University Medical Center Nijmegen The Netherlands
| | - Tania O Crișan
- Department of Medical Genetics Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca Romania
| | - Jelle Zwaag
- Department of Intensive Care and Radboud Center for Infectious diseases (RCI) Radboud University Nijmegen Medical Centre Nijmegen The Netherlands
| | - Elisa Jentho
- Department of Anesthesiology and Intensive Care Medicine Jena University Hospital Friedrich-Schiller University Jena Germany.,Instituto Gulbenkian de Ciência Oeiras Portugal
| | - Matthijs Kox
- Department of Intensive Care and Radboud Center for Infectious diseases (RCI) Radboud University Nijmegen Medical Centre Nijmegen The Netherlands
| | - Peter Pickkers
- Department of Intensive Care and Radboud Center for Infectious diseases (RCI) Radboud University Nijmegen Medical Centre Nijmegen The Netherlands
| | - Frank L van de Veerdonk
- Department of Internal Medicine Radboud Center for Infectious Diseases (RCI) Radboud University Medical Center Nijmegen The Netherlands
| | - Sebastian Weis
- Department of Anesthesiology and Intensive Care Medicine Jena University Hospital Friedrich-Schiller University Jena Germany.,Institute for Infectious Disease and Infection Control Jena University Hospital Friedrich-Schiller University Jena Germany
| | - Egbert Oosterwijk
- Department of Urology Radboud University Nijmegen Medical Centre Nijmegen The Netherlands
| | - Sita H Vermeulen
- Department for Health Evidence Radboud University Medical Center Nijmegen The Netherlands
| | - Mihai G Netea
- Department of Internal Medicine Radboud Center for Infectious Diseases (RCI) Radboud University Medical Center Nijmegen The Netherlands.,Department for Genomics & Immunoregulation, Life and Medical Sciences Institute (LIMES) University of Bonn Bonn Germany
| | - Leo Ab Joosten
- Department of Internal Medicine Radboud Center for Infectious Diseases (RCI) Radboud University Medical Center Nijmegen The Netherlands.,Department of Medical Genetics Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca Romania
| |
Collapse
|
24
|
van Valenberg FJP, Brummelhuis ISG, Lindner LH, Kuhnle F, Wedmann B, Schweizer P, Hossann M, Witjes JA, Oosterwijk E. DPPG 2-Based Thermosensitive Liposomes with Encapsulated Doxorubicin Combined with Hyperthermia Lead to Higher Doxorubicin Concentrations in the Bladder Compared to Conventional Application in Pigs: A Rationale for the Treatment of Muscle-Invasive Bladder Cancer. Int J Nanomedicine 2021; 16:75-88. [PMID: 33447028 PMCID: PMC7802347 DOI: 10.2147/ijn.s280034] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Accepted: 11/10/2020] [Indexed: 12/27/2022] Open
Abstract
Purpose Current treatment options for muscle-invasive bladder cancer (MIBC) are associated with substantial morbidity. Local release of doxorubicin (DOX) from phosphatidyldiglycerol-based thermosensitive liposomes (DPPG2-TSL-DOX) potentiated by hyperthermia (HT) in the bladder wall may result in bladder sparing without toxicity of systemic chemotherapy. We investigated whether this approach, compared to conventional DOX application, increases DOX concentrations in the bladder wall while limiting DOX in essential organs. Materials and Methods Twenty-one pigs were anaesthetized, and a urinary catheter equipped with a radiofrequency-emitting antenna for HT (60 minutes) was placed. Experimental groups consisted of iv low or full dose (20 or 60 mg/m2) DPPG2-TSL-DOX with/without HT, iv low dose (20 mg/m2) free DOX with HT, and full dose (50 mg/50 mL) intravesical DOX with/without HT. After the procedure, animals were immediately sacrificed. HPLC was used to measure DOX levels in the bladder, essential organs and serum, and fluorescence microscopy to evaluate DOX distribution in the bladder wall. Results Iv DPPG2-TSL-DOX with HT resulted in a significantly higher bladder wall DOX concentration which was more homogeneous distributed, than iv and intravesical free DOX administration with HT. Specifically in the detrusor, DPPG2-TSL-DOX with HT led to a >7- and 44-fold higher DOX concentration, compared to iv free DOX with HT and intravesical DOX, respectively. Organ DOX concentrations were significantly lower in heart and kidneys, and similar in liver, spleen and lungs, following iv DPPG2-TSL-DOX with HT, compared to iv free DOX. Intravesical DOX led to the lowest organ DOX concentrations. Conclusion Iv DPPG2-TSL-DOX combined with HT achieved higher DOX concentrations in the bladder wall including the detrusor, compared to conventional iv and intravesical DOX application. In combination with lower DOX accumulation in heart and kidneys, compared to iv free chemotherapy, DPPG2-TSL-DOX with HT has great potential to attain a role as a bladder-sparing treatment for MIBC.
Collapse
Affiliation(s)
| | - Iris S G Brummelhuis
- Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Lars H Lindner
- Department of Medicine III, University Hospital LMU Munich, Munich, Germany
| | - Felix Kuhnle
- Department of Medicine III, University Hospital LMU Munich, Munich, Germany
| | - Barbara Wedmann
- Department of Medicine III, University Hospital LMU Munich, Munich, Germany
| | | | | | - J Alfred Witjes
- Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Egbert Oosterwijk
- Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands
| |
Collapse
|
25
|
Nadar R, Franssen G, Van Dijk N, Codee-van der Schilden K, de Weijert M, Oosterwijk E, Iafisco M, Margiotta N, Heskamp S, van den Beucken J, Leeuwenburgh S. Bone tumor-targeted delivery of theranostic 195mPt-bisphosphonate complexes promotes killing of metastatic tumor cells. Mater Today Bio 2021; 9:100088. [PMID: 33490949 PMCID: PMC7809194 DOI: 10.1016/j.mtbio.2020.100088] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Revised: 11/24/2020] [Accepted: 11/27/2020] [Indexed: 02/07/2023] Open
Abstract
Platinum-based drugs such as cisplatin are very potent chemotherapeutics, whereas radioactive platinum (195mPt) is a rich source of low-energy Auger electrons, which kills tumor cells by damaging DNA. Auger electrons damage cells over a very short range. Consequently, 195mPt-based radiopharmaceuticals should be targeted toward tumors to maximize radiotherapeutic efficacy and minimize Pt-based systemic toxicity. Herein, we show that systemically administered radioactive bisphosphonate-functionalized platinum (195mPt-BP) complexes specifically accumulate in intratibial bone metastatic lesions in mice. The 195mPt-BP complexes accumulate 7.3-fold more effectively in bone 7 days after systemic delivery compared to 195mPt-cisplatin lacking bone-targeting bisphosphonate ligands. Therapeutically, 195mPt-BP treatment causes 4.5-fold more γ-H2AX formation, a biomarker for DNA damage in metastatic tumor cells compared to 195mPt-cisplatin. We show that systemically administered 195mPt-BP is radiotherapeutically active, as evidenced by an 11-fold increased DNA damage in metastatic tumor cells compared to non-radioactive Pt-BP controls. Moreover, apoptosis in metastatic tumor cells is enhanced more than 3.4-fold upon systemic administration of 195mPt-BP vs. radioactive 195mPt-cisplatin or non-radioactive Pt-BP controls. These results provide the first preclinical evidence for specific accumulation and strong radiotherapeutic activity of 195mPt-BP in bone metastatic lesions, which offers new avenues of research on radiotherapeutic killing of tumor cells in bone metastases by Auger electrons.
Collapse
Affiliation(s)
- R.A. Nadar
- Department of Dentistry – Regenerative Biomaterials, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Philips van Leydenlaan 25, 6525 EX, Nijmegen, the Netherlands
| | - G.M. Franssen
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands
| | - N.W.M. Van Dijk
- Department of Dentistry – Regenerative Biomaterials, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Philips van Leydenlaan 25, 6525 EX, Nijmegen, the Netherlands
| | | | - M. de Weijert
- Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, 6500 HB, Nijmegen, the Netherlands
| | - E. Oosterwijk
- Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, 6500 HB, Nijmegen, the Netherlands
| | - M. Iafisco
- Institute of Science and Technology for Ceramics (ISTEC), National Research Council (CNR), Via Granarolo 64, 48018, Faenza, Italy
| | - N. Margiotta
- Dipartimento di Chimica, Università degli Studi di Bari Aldo Moro, Via E. Orabona 4, 70125 Bari, Italy
| | - S. Heskamp
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands
| | - J.J.J.P. van den Beucken
- Department of Dentistry – Regenerative Biomaterials, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Philips van Leydenlaan 25, 6525 EX, Nijmegen, the Netherlands
| | - S.C.G. Leeuwenburgh
- Department of Dentistry – Regenerative Biomaterials, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Philips van Leydenlaan 25, 6525 EX, Nijmegen, the Netherlands
- Institute of Science and Technology for Ceramics (ISTEC), National Research Council (CNR), Via Granarolo 64, 48018, Faenza, Italy
| |
Collapse
|
26
|
Liu K, Veenendaal T, Wiendels M, Ruiz-Zapata AM, van Laar J, Kyranas R, Enting H, van Cranenbroek B, Koenen HJPM, Mihaila SM, Oosterwijk E, Kouwer PHJ. Synthetic Extracellular Matrices as a Toolbox to Tune Stem Cell Secretome. ACS Appl Mater Interfaces 2020; 12:56723-56730. [PMID: 33305561 PMCID: PMC7760093 DOI: 10.1021/acsami.0c16208] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
The application of stem cell-derived secretome in regenerative therapies offers the key advantage that instead of the stem cells, only their effective paracrine compounds are in vivo delivered. Ideally, the secretome can be steered by the culture conditions of the stem cells. So far, most studies use stem cells cultured on stiff plastic substrates, not representative of their native 3D environment. In this study, cells are cultured inside synthetic polyisocyanide (PIC)-based hydrogels, which are minimal, tailorable, and highly reproducible biomimetic matrices. Secretome analysis of human adipose-derived stem cells (multiplex, ELISA) displays that matrix manipulation is a powerful tool to direct the secretome composition. As an example, cells in nonadherent PIC gels secrete increased levels of IL-10 and the conditioned media from 3D culture accelerate wound closure. In all, our PIC-based approach opens the door to dedicated matrix design to engineer the secretome for custom applications.
Collapse
Affiliation(s)
- Kaizheng Liu
- Institute
for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands
| | - Tomas Veenendaal
- Institute
for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands
| | - Maury Wiendels
- Institute
for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands
| | - Alejandra M. Ruiz-Zapata
- Radboud
Institute for Molecular Life Sciences, Department of Obstetrics and
Gynecology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
| | - Justin van Laar
- Institute
for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands
| | - Rafail Kyranas
- Institute
for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands
| | - Hilde Enting
- Institute
for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands
| | - Bram van Cranenbroek
- Lab
Medical Immunology, Laboratory Medicine, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands
| | - Hans J. P. M. Koenen
- Lab
Medical Immunology, Laboratory Medicine, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands
| | - Silvia M. Mihaila
- Utrecht
Institute for Pharmaceutical Sciences, Division of Pharmacology, Utrecht University, 3854 CG Utrecht, The Netherlands
| | - Egbert Oosterwijk
- Radboud
Institute for Molecular Life Sciences, Department of Urology, Radboud University Medical Centre, Geert Grooteplein 26-28, P.O.
Box 9101, 6500 HB Nijmegen, The Netherlands
| | - Paul H. J. Kouwer
- Institute
for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands
| |
Collapse
|
27
|
Parfenov VA, Koudan EV, Krokhmal AA, Annenkova EA, Petrov SV, Pereira FDAS, Karalkin PA, Nezhurina EK, Gryadunova AA, Bulanova EA, Sapozhnikov OA, Tsysar SA, Liu K, Oosterwijk E, van Beuningen H, van der Kraan P, Granneman S, Engelkamp H, Christianen P, Kasyanov V, Khesuani YD, Mironov VA. Biofabrication of a Functional Tubular Construct from Tissue Spheroids Using Magnetoacoustic Levitational Directed Assembly. Adv Healthc Mater 2020; 9:e2000721. [PMID: 32809273 DOI: 10.1002/adhm.202000721] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Revised: 07/06/2020] [Indexed: 12/15/2022]
Abstract
In traditional tissue engineering, synthetic or natural scaffolds are usually used as removable temporal support, which involves some biotechnology limitations. The concept of "scaffield" approach utilizing the physical fields instead of biomaterial scaffold has been proposed recently. In particular, a combination of intense magnetic and acoustic fields can enable rapid levitational bioassembly of complex-shaped 3D tissue constructs from tissue spheroids at low concentration of paramagnetic agent (gadolinium salt) in the medium. In the current study, the tissue spheroids from human bladder smooth muscle cells (myospheres) are used as building blocks for assembling the tubular 3D constructs. Levitational assembly is accomplished at low concentrations of gadolinium salts in the high magnetic field at 9.5 T. The biofabricated smooth muscle constructs demonstrate contraction after the addition of vasoconstrictive agent endothelin-1. Thus, hybrid magnetoacoustic levitational bioassembly is considered as a new technology platform in the emerging field of formative biofabrication. This novel technology of scaffold-free, nozzle-free, and label-free bioassembly opens a unique opportunity for rapid biofabrication of 3D tissue and organ constructs with complex geometry.
Collapse
Affiliation(s)
- Vladislav A. Parfenov
- Laboratory for Biotechnological Research “3D Bioprinting Solutions” Moscow 115409 Russia
- A. A. Baikov Institute of Metallurgy and Material Science Russian Academy of Sciences Moscow 119334 Russia
| | - Elizaveta V. Koudan
- Laboratory for Biotechnological Research “3D Bioprinting Solutions” Moscow 115409 Russia
| | - Alisa A. Krokhmal
- Department of Physics Lomonosov Moscow State University Moscow 119991 Russia
| | - Elena A. Annenkova
- Laboratory for Biotechnological Research “3D Bioprinting Solutions” Moscow 115409 Russia
| | - Stanislav V. Petrov
- Laboratory for Biotechnological Research “3D Bioprinting Solutions” Moscow 115409 Russia
| | | | - Pavel A. Karalkin
- P. A. Hertsen Moscow Oncology Research Center National Medical Research Radiological Center Moscow 125284 Russia
- I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) Moscow 119991 Russia
| | - Elizaveta K. Nezhurina
- P. A. Hertsen Moscow Oncology Research Center National Medical Research Radiological Center Moscow 125284 Russia
| | - Anna A. Gryadunova
- Laboratory for Biotechnological Research “3D Bioprinting Solutions” Moscow 115409 Russia
| | - Elena A. Bulanova
- Laboratory for Biotechnological Research “3D Bioprinting Solutions” Moscow 115409 Russia
| | - Oleg A. Sapozhnikov
- Department of Physics Lomonosov Moscow State University Moscow 119991 Russia
| | - Sergey A. Tsysar
- Department of Physics Lomonosov Moscow State University Moscow 119991 Russia
| | - Kaizheng Liu
- Department of Urology Radboud University Medical Center Nijmegen 9102 The Netherlands
| | - Egbert Oosterwijk
- Department of Urology Radboud University Medical Center Nijmegen 9102 The Netherlands
| | - Henk van Beuningen
- Department of Experimental Rheumatology Radboud University Medical Center Nijmegen 9102 The Netherlands
| | - Peter van der Kraan
- Department of Experimental Rheumatology Radboud University Medical Center Nijmegen 9102 The Netherlands
| | - Sanne Granneman
- High Field Magnet Laboratory (HFML‐EMFL) Radboud University Toernooiveld 7 Nijmegen 9010 The Netherlands
| | - Hans Engelkamp
- High Field Magnet Laboratory (HFML‐EMFL) Radboud University Toernooiveld 7 Nijmegen 9010 The Netherlands
| | - Peter Christianen
- High Field Magnet Laboratory (HFML‐EMFL) Radboud University Toernooiveld 7 Nijmegen 9010 The Netherlands
| | - Vladimir Kasyanov
- Riga Stradins University Riga LV‐1007 Latvia
- Riga Technical University Riga LV‐1658 Latvia
| | - Yusef D. Khesuani
- Laboratory for Biotechnological Research “3D Bioprinting Solutions” Moscow 115409 Russia
| | - Vladimir A. Mironov
- Laboratory for Biotechnological Research “3D Bioprinting Solutions” Moscow 115409 Russia
- I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) Moscow 119991 Russia
| |
Collapse
|
28
|
Post WM, Ruiz-Zapata AM, Grens H, de Vries RBM, Poelmans G, Coenen MJH, Janssen DAW, Heesakkers JPFA, Oosterwijk E, Kluivers KB. Genetic variants and expression changes in urgency urinary incontinence: A systematic review. Neurourol Urodyn 2020; 39:2089-2110. [PMID: 32949220 PMCID: PMC7692907 DOI: 10.1002/nau.24512] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Revised: 08/17/2020] [Accepted: 09/04/2020] [Indexed: 12/12/2022]
Abstract
Aim To perform a systematic review summarizing the knowledge of genetic variants, gene, and protein expression changes in humans and animals associated with urgency urinary incontinence (UUI) and to provide an overview of the known molecular mechanisms related to UUI. Methods A systematic search was performed on March 2, 2020, in PubMed, Embase, Web of Science, and the Cochrane library. Retrieved studies were screened for eligibility. The risk of bias was assessed using the ROBINS‐I (human) and SYRCLE (animal) tool. Data were presented in a structured manner and in the case of greater than five studies on a homogeneous outcome, a meta‐analysis was performed. Results Altogether, a total of 10,785 records were screened of which 37 studies met the inclusion criteria. Notably, 24/37 studies scored medium‐high to high on risk of bias, affecting the value of the included studies. The analysis of 70 unique genes and proteins and three genome‐wide association studies showed that specific signal transduction pathways and inflammation are associated with UUI. A meta‐analysis on the predictive value of urinary nerve growth factor (NGF) levels showed that increased urinary NGF levels correlate with UUI. Conclusion The collective evidence showed the involvement of two molecular mechanisms (signal transduction and inflammation) and NGF in UUI, enhancing our understanding of the pathophysiology of UUI. Unfortunately, the risk of bias was medium‐high to high for most studies and the value of many observations remains unclear. Future studies should focus on elucidating how deficits in the two identified molecular mechanisms contribute to UUI and should avoid bias.
Collapse
Affiliation(s)
- Wilke M Post
- Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Alejandra M Ruiz-Zapata
- Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Hilde Grens
- Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Rob B M de Vries
- Department for Health Evidence, SYRCLE, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Geert Poelmans
- Department of Human Genetics, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Marieke J H Coenen
- Department of Human Genetics, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Dick A W Janssen
- Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
| | | | - Egbert Oosterwijk
- Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Kirsten B Kluivers
- Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands
| |
Collapse
|
29
|
Ruiz-Zapata AM, Heinz A, Kerkhof MH, van de Westerlo-van Rijt C, Schmelzer CEH, Stoop R, Kluivers KB, Oosterwijk E. Extracellular Matrix Stiffness and Composition Regulate the Myofibroblast Differentiation of Vaginal Fibroblasts. Int J Mol Sci 2020; 21:ijms21134762. [PMID: 32635512 PMCID: PMC7369731 DOI: 10.3390/ijms21134762] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Revised: 06/29/2020] [Accepted: 06/30/2020] [Indexed: 12/26/2022] Open
Abstract
Fibroblast to myofibroblast differentiation is a key feature of wound-healing in soft tissues, including the vagina. Vaginal fibroblasts maintain the integrity of the vaginal wall tissues, essential to keep pelvic organs in place and avoid pelvic organ prolapse (POP). The micro-environment of vaginal tissues in POP patients is stiffer and has different extracellular matrix (ECM) composition than healthy vaginal tissues. In this study, we employed a series of matrices with known stiffnesses, as well as vaginal ECMs, in combination with vaginal fibroblasts from POP and healthy tissues to investigate how matrix stiffness and composition regulate myofibroblast differentiation in vaginal fibroblasts. Stiffness was positively correlated to production of α-smooth muscle actin (α-SMA). Vaginal ECMs induced myofibroblast differentiation as both α-SMA and collagen gene expressions were increased. This differentiation was more pronounced in cells seeded on POP-ECMs that were stiffer than those derived from healthy tissues and had higher collagen and elastin protein content. We showed that stiffness and ECM content regulate vaginal myofibroblast differentiation. We provide preliminary evidence that vaginal fibroblasts might recognize POP-ECMs as scar tissues that need to be remodeled. This is fundamentally important for tissue repair, and provides a rational basis for POP disease modelling and therapeutic innovations in vaginal reconstruction.
Collapse
Affiliation(s)
- Alejandra M. Ruiz-Zapata
- Department of Obstetrics and Gynecology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; (C.v.d.W.-v.R.); (K.B.K.)
- Correspondence:
| | - Andrea Heinz
- Department of Pharmacy, LEO Foundation Center for Cutaneous Drug Delivery, University of Copenhagen, 2100 Copenhagen, Denmark;
| | - Manon H. Kerkhof
- Curilion, Women’s Health Centre, 2015 BJ Haarlem, The Netherlands;
| | - Cindy van de Westerlo-van Rijt
- Department of Obstetrics and Gynecology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; (C.v.d.W.-v.R.); (K.B.K.)
| | - Christian E. H. Schmelzer
- Department of Biological and Macromolecular Materials, Fraunhofer Institute for Microstructure Materials and Systems IMWS, 06120 Halle (Saale), Germany;
| | - Reinout Stoop
- TNO Metabolic Health Research, 2301 DA Leiden, The Netherlands;
| | - Kirsten B. Kluivers
- Department of Obstetrics and Gynecology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; (C.v.d.W.-v.R.); (K.B.K.)
| | - Egbert Oosterwijk
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands;
| |
Collapse
|
30
|
Van Oostenbrugge T, Langenhuijsen J, Oosterwijk E, Boerman O, Jenniskens S, Oyen W, Fütterer J, Mulders P. Early follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with ¹¹¹In-girentuximab. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33922-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
31
|
Merkx R, Kip A, Franssen G, Oosterwijk E, Morgenstern A, Bruchertseifer F, Wheatcroft M, Yan E, Rijpkema M, Heskamp S, Mulders P. Therapeutic efficacy and tolerability of [225Ac]Ac-DOTA-hG250 targeted alpha therapy in a clear cell renal cell carcinoma mice model. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33580-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
32
|
Brummelhuis I, Lev G, Van Hattum J, Witjes J, Oosterwijk E. Bladder cancer cell proliferation is inhibited by radiofrequency treatment alone and combined with hyperthermia and chemotherapeutic agents in vitro. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33649-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
33
|
Lommen K, Feng Z, Oberije CJ, van de Wetering AJP, Odeh S, Koch A, Aarts MJB, van Roermund JG, Schouten LJ, Oosterwijk E, Vaes N, Masclee AAM, Carvalho B, Meijer GA, Zeegers MP, Herman JG, Tjan-Heijnen VC, Melotte V, van Engeland M, Smits K. Abstract A62: Clinical translation of liquid biopsy DNA methylation biomarkers: Lessons from two systematic reviews. Clin Cancer Res 2020. [DOI: 10.1158/1557-3265.liqbiop20-a62] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Very few (<0.1%) of DNA methylation biomarkers are eventually translated into clinical practice, even though over 5,000 have been published over the last decades. In an attempt to create an overview of the current evidence on these markers, we performed two systematic reviews on diagnostic DNA methylation biomarkers in liquid biopsies, for colorectal cancer (CRC) and renal cell carcinoma (RCC) (1). Here, we present the evidence of these systematic reviews and provide novel recommendations to improve the current clinical translation of DNA methylation biomarkers.
Methods: For CRC, we identified 109 bodily fluid biomarker studies published before January 2019 in PubMed, Embase, Cochrane Library, or Google Scholar. For RCC, we identified 6 liquid biopsy studies up to January 2019 in these databases. Data extraction (study design, patient characteristics, disease stage, tumor location, technical assays, diagnostic measures) was performed on published reports. STARD criteria and Level of Evidence (LoE) were registered to assess reporting quality and strength for clinical translation, and forest plots were generated to summarize diagnostic performance of the biomarkers.
Findings: Our systematic literature search revealed multiple issues that hamper the development of DNA methylation biomarkers for RCC and CRC diagnosis, including methodologic and technical heterogeneity and lack of validation or clinical translation. Among the most important issues were a lack of translation from tissue into liquid biopsy; for CRC 88/389 (23%) CRC markers were studied in liquid biopsies, and for RCC these numbers were 15/44 (34%). In addition, results showed a lack of independent validation, with 37/88 (42%) CRC markers and 9/15 (60%) RCC markers in liquid biopsies studied in more than one study or study population. Also, inappropriate marker identification and primer design, lack of true clinical need definition, and low reporting quality were issues that were recognized in our systematic literature searches. These issues all hamper the development of the field, keep the LoE low, and hinder the translation of DNA methylation biomarkers into clinical tests.
Interpretation: Our systematic literature searches revealed that major requirements to develop clinically relevant diagnostic DNA methylation markers are often lacking. To avoid the resulting research waste, clinical needs, intended biomarker use, and independent validation should be better considered prior to study design. In addition, improved reporting quality would facilitate meta-analysis, thereby increasing LoE and enabling clinical translation.
Reference: 1. Lommen et al. Eur Urol Oncol 2019; https://doi.org/10.1016/j.euo.2019.07.011.
Citation Format: Kim Lommen, Zheng Feng, Cary J.G. Oberije, Alouisa J. P. van de Wetering, Selena Odeh, Alexander Koch, Maureen J. B. Aarts, Joep G. van Roermund, Leo J. Schouten, Egbert Oosterwijk, Nathalie Vaes, Ad A. M. Masclee, Beatriz Carvalho, Gerrit A. Meijer, Maurice P. Zeegers, James G. Herman, Vivianne C. Tjan-Heijnen, Veerle Melotte, Manon van Engeland, Kim Smits. Clinical translation of liquid biopsy DNA methylation biomarkers: Lessons from two systematic reviews [abstract]. In: Proceedings of the AACR Special Conference on Advances in Liquid Biopsies; Jan 13-16, 2020; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(11_Suppl):Abstract nr A62.
Collapse
Affiliation(s)
- Kim Lommen
- 1Department of Pathology, GROW—School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands,
| | - Zheng Feng
- 1Department of Pathology, GROW—School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands,
| | - Cary J.G. Oberije
- 2Department of Pathology & Department of Precision Medicine, GROW—School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands,
| | - Alouisa J. P. van de Wetering
- 3Division of Gastroenterology and Hepatology, Department of Internal Medicine, GROW—School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands,
| | - Selena Odeh
- 1Department of Pathology, GROW—School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands,
| | - Alexander Koch
- 1Department of Pathology, GROW—School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands,
| | - Maureen J. B. Aarts
- 4Department of Medical Oncology, GROW—School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands,
| | - Joep G. van Roermund
- 5Department of Urology, GROW—School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands,
| | - Leo J. Schouten
- 6Department of Epidemiology, GROW—School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands,
| | - Egbert Oosterwijk
- 7Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands,
| | - Nathalie Vaes
- 1Department of Pathology, GROW—School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands,
| | - Ad A. M. Masclee
- 8Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, the Netherlands,
| | - Beatriz Carvalho
- 9Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands,
| | - Gerrit A. Meijer
- 9Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands,
| | - Maurice P. Zeegers
- 10Department of Complex Genetics, NUTRIM School of Nutrition and Translational Research in Metabolism & CAPHRI – Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, the Netherlands,
| | - James G. Herman
- 11Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA
| | - Vivianne C. Tjan-Heijnen
- 4Department of Medical Oncology, GROW—School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands,
| | - Veerle Melotte
- 1Department of Pathology, GROW—School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands,
| | - Manon van Engeland
- 1Department of Pathology, GROW—School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands,
| | - Kim Smits
- 1Department of Pathology, GROW—School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands,
| |
Collapse
|
34
|
Pot M, Mihaila SM, te Brinke D, van der Borg G, Oosterwijk E, Daamen WF, van Kuppevelt TH. Introduction of Specific 3D Micromorphologies in Collagen Scaffolds Using Odd and Even Dicarboxylic Acids. ACS Omega 2020; 5:3908-3916. [PMID: 32149217 PMCID: PMC7057318 DOI: 10.1021/acsomega.9b03350] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/09/2019] [Accepted: 02/10/2020] [Indexed: 05/03/2023]
Abstract
The construction of scaffolds and subsequent incorporation of cells and biologics have been widely investigated to regenerate damaged tissues. Scaffolds act as a template to guide tissue formation, and their characteristics have a considerable impact on the regenerative process. Whereas many technologies exist to induce specific two-dimensional (2D) morphologies into biomaterials, the introduction of three-dimensional (3D) micromorphologies into individual pore walls of scaffolds produced from biological molecules such as collagen poses a challenge. We here report the use of dicarboxylic acids to induce specific micromorphologies in collagen scaffolds and evaluate their effect on cellular migration and differentiation. Insoluble type I collagen fibrils were suspended in monocarboxylic and dicarboxylic acids of different concentrations, and unidirectional and random pore scaffolds were constructed by freezing and lyophilization. The application of various acids and concentrations resulted in variations in 3D micromorphologies, including wall structure, wall thickness, and pore size. The use of dicarboxylic acids resulted in acid-specific micromorphologies, whereas monocarboxylic acids did not. Dicarboxylic acids with an odd or even number of C-atoms resulted in frayed/fibrillar or smooth wall structures, respectively, with varying appearances. The formation of micromorphologies was concentration-dependent. In vitro analysis indicated the cytocompatibility of scaffolds, and micromorphology-related cell behavior was indicated by enhanced myosin staining and myosin heavy chain gene expression for C2C12 myoblasts cultured on scaffolds with frayedlike micromorphologies compared to those with smooth micromorphologies. In conclusion, porous collagen scaffolds with various intrawall 3D micromorphologies can be constructed by application of dicarboxylic acids, superimposing the second level of morphology to the overall scaffold structure. Acid crystal formation is key to the specific micromorphologies observed and can be explained by the odd/even theory for dicarboxylic acids. Scaffolds with a 3D micrometer-defined topography may be used as a screening platform to select optimal substrates for the regeneration of specific tissues.
Collapse
Affiliation(s)
- Michiel
W. Pot
- Department
of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands
| | - Silvia M. Mihaila
- Department
of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands
| | - Dana te Brinke
- Department
of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands
| | - Guus van der Borg
- Department
of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands
| | - Egbert Oosterwijk
- Department
of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands
| | - Willeke F. Daamen
- Department
of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands
| | - Toin H. van Kuppevelt
- Department
of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands
| |
Collapse
|
35
|
Merkx R, Heskamp S, Mulders P, Rijpkema M, Oosterwijk E, Wheatcroft M, Kip A, Morgenstern A, Bruchertseifer F. 225Ac-labeled Girentuximab for Targeted Alpha Therapy of CAIX-expressing Renal Cell Cancer Xenografts. J Med Imaging Radiat Sci 2019. [DOI: 10.1016/j.jmir.2019.11.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
36
|
van Oostenbrugge TJ, Langenhuijsen JF, Oosterwijk E, Boerman OC, Jenniskens SF, Oyen WJG, Fütterer JJ, Mulders PFA. Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111In-girentuximab. Eur J Nucl Med Mol Imaging 2019; 47:1864-1870. [PMID: 31768601 PMCID: PMC7299921 DOI: 10.1007/s00259-019-04613-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2019] [Accepted: 11/11/2019] [Indexed: 11/24/2022]
Abstract
Purpose Detection of residual or recurrent vital renal tumor on follow-up (FU) cross-sectional imaging after ablative therapy is challenging. The specific and high expression levels of carbonic anhydrase IX (CAIX) in clear cell renal cell carcinoma (ccRCC) makes it a suitable target for imaging using radiolabeled anti-CAIX antibody girentuximab. The objective of this study was to evaluate the feasibility of targeted FU imaging 1 month after cryoablation of ccRCC using single photon emission computed tomography (SPECT) after 111In-labeled girentuximab administration. Methods In this prospective study 16 patients underwent 111In-girentuximab-SPECT before MR-guided renal cryoablation between February 2015 and September 2018. In case of tumor targeting 111In-girentuximab-SPECT was repeated 1 month following MR-guided cryoablation. Presence of residual or recurrent vital tumor was assessed on contrast-enhanced cross-sectional imaging during further FU. The standard FU imaging protocol consisted of MRI/CT scans at 1, 3, 6, 12, and 18 months and annually thereafter. Results A total of 10 (63%) patients showed positive tumor targeting on 111In-girentuximab-SPECT before cryoablation and 9 ( 56%) were eligible to undergo FU SPECT. Of the 9 111In-girentuximab-SPECT FU scans, 8 (89%) were considered negative. One (11%) scan showed uptake suggestive for residual vital tumor. Six months after treatment, FU CT showed contrast enhancement suggestive for residual/recurrent disease in the ablated zone at the site of the 111In-girentuximab uptake after treatment. During a mean FU of 21 months (range 1–33) no other cases with residual/recurrent disease were detected. Conclusion FU imaging with 111In-girentuximab-SPECT is feasible after ccRCC cryoablation and may contribute to early detection of residual or recurrent disease.
Collapse
Affiliation(s)
- Tim J van Oostenbrugge
- Department of Urology, Radboud University Medical Center, 6500, HB, Nijmegen, the Netherlands. .,Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
| | - Johan F Langenhuijsen
- Department of Urology, Radboud University Medical Center, 6500, HB, Nijmegen, the Netherlands
| | - Egbert Oosterwijk
- Department of Urology, Radboud University Medical Center, 6500, HB, Nijmegen, the Netherlands
| | - Otto C Boerman
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Sjoerd F Jenniskens
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Wim J G Oyen
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.,Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, the Netherlands
| | - Jurgen J Fütterer
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Peter F A Mulders
- Department of Urology, Radboud University Medical Center, 6500, HB, Nijmegen, the Netherlands
| |
Collapse
|
37
|
Janke HP, de Jonge PK, Feitz WF, Oosterwijk E. Reconstruction Strategies of the Ureter and Urinary Diversion Using Tissue Engineering Approaches. Tissue Engineering Part B: Reviews 2019; 25:237-248. [DOI: 10.1089/ten.teb.2018.0345] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Heinz P. Janke
- Department of Urology, Radboud Institute for Molecular Life Science, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Paul K.J.D. de Jonge
- Department of Urology, Radboud Institute for Molecular Life Science, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Wout F.J. Feitz
- Department of Urology, Radboud Institute for Molecular Life Science, Radboud University Medical Center, Nijmegen, The Netherlands
- Radboudumc Amalia Children's Hospital, Nijmegen, The Netherlands
| | - Egbert Oosterwijk
- Department of Urology, Radboud Institute for Molecular Life Science, Radboud University Medical Center, Nijmegen, The Netherlands
| |
Collapse
|
38
|
van den Heuvel CNAM, van Ewijk A, Zeelen C, de Bitter T, Huynen M, Mulders P, Oosterwijk E, Leenders WPJ. Molecular Profiling of Druggable Targets in Clear Cell Renal Cell Carcinoma Through Targeted RNA Sequencing. Front Oncol 2019; 9:117. [PMID: 30881919 PMCID: PMC6407434 DOI: 10.3389/fonc.2019.00117] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2018] [Accepted: 02/11/2019] [Indexed: 01/05/2023] Open
Abstract
Clear cell renal cell carcinoma (ccRCC) comprises more than 80% of all renal cancers and when metastasized leads to a 5-year survival rate of only 10%. The high rate of therapy failure and resistance development calls for reliable methods that provide information on the actionable biological pathways and predict optimal treatment protocols for individual patients. We here applied targeted RNA sequencing (t/RNA-NGS) using single molecule Molecular Inversion Probes on tumor nephrectomy samples of five ccRCC patients, comparing tumor with healthy kidney tissues. Transcriptome profiling focused on expression of genes with involvement in ccRCC biology that can be targeted with clinically available drugs. Results confirm high expression of vascular endothelial growth factor-A (VEGF-A) in tumor tissue relative to healthy-appearing kidney, in line with the angiogenic nature of ccRCC. PDGFRα and KIT, targets of the multi-kinase inhibitor sunitinib which is one of the current choices of first-line drug in metastasized ccRCC patients, were expressed at relatively low levels in tumor tissues, whereas significantly increased in normal kidney. Of all measured druggable tyrosine kinases, MET, AXL, or EGFR were expressed at higher levels in tumors than in normal kidney tissues, although intertumor differences were observed. Using cancer cell lines we show that t/RNA-NGS gene expression profiles can be used to predict in vitro sensitivity to targeted drugs. In conclusion, t/RNA-NGS analysis may provide insights into the (druggable) molecular make-up of individual renal cancers, and may guide personalized therapy of renal cell cancers.
Collapse
Affiliation(s)
| | - Anne van Ewijk
- Department of Biochemistry, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands
| | - Carolien Zeelen
- Department of Pathology, Radboud University Medical Centre, Nijmegen, Netherlands
| | - Tessa de Bitter
- Department of Pathology, Radboud University Medical Centre, Nijmegen, Netherlands
| | - Martijn Huynen
- Center for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands
| | - Peter Mulders
- Department of Urology, Radboud University Medical Centre, Nijmegen, Netherlands
| | - Egbert Oosterwijk
- Department of Urology, Radboud University Medical Centre, Nijmegen, Netherlands
| | - William P J Leenders
- Department of Biochemistry, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands
| |
Collapse
|
39
|
Merkx R, Heskamp S, Mulders P, Rijpkema M, Oosterwijk E, Wheatcroft M, Kip A, Morgenstern A, Bruchertseifer F. 225Ac-labeled Girentuximab for Targeted Alpha Therapy of CAIX-expressing Renal Cell Cancer Xenografts. J Med Imaging Radiat Sci 2019. [DOI: 10.1016/j.jmir.2019.03.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
40
|
Abstract
![]()
One of the promises
of synthetic materials in cell culturing is
that control over their molecular structures may ultimately be used
to control their biological processes. Synthetic polymer hydrogels
from polyisocyanides (PIC) are a new class of minimal synthetic biomaterials
for three-dimensional cell culturing. The macromolecular lengths and
densities of biofunctional groups that decorate the polymer can be
readily manipulated while preserving the intrinsic nonlinear mechanics,
a feature commonly displayed by fibrous biological networks. In this
work, we propose the use of PIC gels as cell culture platforms with
decoupled mechanical inputs and biological cues. For this purpose,
different types of cells were encapsulated in PIC gels of tailored
compositions that systematically vary in adhesive peptide (GRGDS)
density, polymer length, and concentration; with the last two parameters
controlling the gel mechanics. Both cancer and smooth muscle cells
grew into multicellular spheroids with proliferation rates that depend
on the adhesive GRGDS density, regardless of the polymer length, suggesting
that for these cells, the biological input prevails over the mechanical
cues. In contrast, human adipose-derived stem cells do not form spheroids
but rather spread out. We find that the morphological changes strongly
depend on the adhesive ligand density and the network mechanics; gels
with the highest GRGDS densities and the strongest stiffening response
to stress show the strongest spreading. Our results highlight the
role of the nonlinear mechanics of the extracellular matrix and its
synthetic mimics in the regulation of cell functions.
Collapse
Affiliation(s)
- Kaizheng Liu
- Radboud University , Institute for Molecules and Materials , Heyendaalseweg 135 , 6525 AJ Nijmegen , The Netherlands
| | - Silvia M Mihaila
- Radboud University Medical Centre and Radboudumc Amalia Childern's hospital , Radboud Institute for Molecular Life Sciences, Department of Urology , Geert Grooteplein 26-28 , PO Box 9101, 6500 HB Nijmegen , The Netherlands
| | - Alan Rowan
- The University of Queensland, Australian Institute for Bioengineering and Nanotechnology , Brisbane , QLD 4072 , Australia
| | - Egbert Oosterwijk
- Radboud University Medical Centre and Radboudumc Amalia Childern's hospital , Radboud Institute for Molecular Life Sciences, Department of Urology , Geert Grooteplein 26-28 , PO Box 9101, 6500 HB Nijmegen , The Netherlands
| | - Paul H J Kouwer
- Radboud University , Institute for Molecules and Materials , Heyendaalseweg 135 , 6525 AJ Nijmegen , The Netherlands
| |
Collapse
|
41
|
Versteegden LR, Sloff M, Hoogenkamp HR, Pot MW, Pang J, Hafmans TG, de Jong T, Smit TH, Leeuwenburgh SC, Oosterwijk E, Feitz WF, Daamen WF, van Kuppevelt TH. A salt-based method to adapt stiffness and biodegradability of porous collagen scaffolds. RSC Adv 2019; 9:36742-36750. [PMID: 35539087 PMCID: PMC9075161 DOI: 10.1039/c9ra06651a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Accepted: 10/26/2019] [Indexed: 11/21/2022] Open
Abstract
Type I collagen scaffolds for tissue reconstruction often have impaired mechanical characteristics such as limited stiffness and lack of strength. In this study, a new technique is presented to fine-tune stiffness and biodegradability of collagen scaffolds by treatment with concentrated salt solutions. Collagen scaffolds were prepared by a casting, freezing and lyophilization process. Scaffolds were treated with 90% saturated salt solutions, the salts taken from the Hofmeister series, followed by chemical crosslinking. Treatment with salts consisting of a divalent cation in combination with a monovalent anion, e.g. CaCl2, resulted in fast shrinkage of the scaffolds up to approximately 10% of the original surface area. Effective salts were mostly at the chaotropic end of the Hofmeister series. Shrunken scaffolds were more than 10 times stiffer than non-shrunken control scaffolds, and displayed reduced pore sizes and swollen, less organized collagen fibrils. The effect could be pinpointed to the level of individual collagen molecules and indicates the shrinking effect to be driven by disruption of stabilizing hydrogen bonds within the triple helix. No calcium deposits remained in CaCl2 treated scaffolds. Subcutaneous implantation in rats showed similar biocompatibility compared to H2O and NaCl treated scaffolds, but reduced cellular influx and increased structural integrity without signs of major degradation after 3 months. In conclusion, high concentrations of chaotropic salts can be used to adjust the mechanical characteristics of collagen scaffolds without affecting biocompatibility. This technique may be used in regenerative medicine to stiffen collagen scaffolds to better comply with the surrounding tissues, but may also be applied for e.g. slow release drug delivery systems. Treatment of collagen scaffolds with salts taken from the Hofmeister series induce fast shrinkage and increased stiffness. Subcutaneous implantation in rats shows similar biocompatibility as control scaffolds, but reduced cellular influx and increased structural integrity.![]()
Collapse
Affiliation(s)
- Luuk R. Versteegden
- Department of Biochemistry, Route 280
- Radboud Institute for Molecular Life Sciences
- Radboud university medical center
- 6500 HB Nijmegen
- The Netherlands
| | - Marije Sloff
- Department of Urology, Route 267
- Radboud Institute for Molecular Life Sciences
- Radboud university medical center
- 6500 HB Nijmegen
- The Netherlands
| | - Henk R. Hoogenkamp
- Department of Biochemistry, Route 280
- Radboud Institute for Molecular Life Sciences
- Radboud university medical center
- 6500 HB Nijmegen
- The Netherlands
| | - Michiel W. Pot
- Department of Biochemistry, Route 280
- Radboud Institute for Molecular Life Sciences
- Radboud university medical center
- 6500 HB Nijmegen
- The Netherlands
| | - Jeffrey Pang
- Department of Biochemistry, Route 280
- Radboud Institute for Molecular Life Sciences
- Radboud university medical center
- 6500 HB Nijmegen
- The Netherlands
| | - Theo G. Hafmans
- Department of Biochemistry, Route 280
- Radboud Institute for Molecular Life Sciences
- Radboud university medical center
- 6500 HB Nijmegen
- The Netherlands
| | - Thijs de Jong
- Department of Medical Biology and Department of Orthopaedics
- Amsterdam Movement Sciences
- Amsterdam University Medical Centers
- 1085AZ Amsterdam
- The Netherlands
| | - Theo H. Smit
- Department of Medical Biology and Department of Orthopaedics
- Amsterdam Movement Sciences
- Amsterdam University Medical Centers
- 1085AZ Amsterdam
- The Netherlands
| | - Sander C. Leeuwenburgh
- Department of Dentistry, Route 309
- Radboud university medical center
- 6500 HB Nijmegen
- The Netherlands
| | - Egbert Oosterwijk
- Department of Urology, Route 267
- Radboud Institute for Molecular Life Sciences
- Radboud university medical center
- 6500 HB Nijmegen
- The Netherlands
| | - Wout F. Feitz
- Department of Urology, Route 267
- Radboud Institute for Molecular Life Sciences
- Radboud university medical center
- 6500 HB Nijmegen
- The Netherlands
| | - Willeke F. Daamen
- Department of Biochemistry, Route 280
- Radboud Institute for Molecular Life Sciences
- Radboud university medical center
- 6500 HB Nijmegen
- The Netherlands
| | - Toin H. van Kuppevelt
- Department of Biochemistry, Route 280
- Radboud Institute for Molecular Life Sciences
- Radboud university medical center
- 6500 HB Nijmegen
- The Netherlands
| |
Collapse
|
42
|
Nagao K, Shinohara N, Smit F, de Weijert M, Jannink S, Owada Y, Mulders P, Oosterwijk E, Matsuyama H. Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma. BMC Cancer 2018; 18:1114. [PMID: 30442117 PMCID: PMC6238291 DOI: 10.1186/s12885-018-5060-8] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2017] [Accepted: 11/07/2018] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND To identify potential therapeutic target in clear cell renal cell carcinoma (ccRCC), we performed a transcriptome analysis. Our analysis showed that fatty acid binding protein 7 (FABP7) has the highest mean differential overexpression in ccRCC compared to normal kidney. We aimed to investigate the significance of FABP7 in ccRCC. METHODS Immunohistochemical staining for 40 advanced ccRCC cases was performed to investigate correlation between clinicopathological parameters and FABP7. They were composed of 40-83 years old cases with 33 male, 22 cases with pT ≥ 3, 19 cases with M1, and 16 cases with grade 3. The effect of gene knockdown was analysed by a cell viability assay and invasion assay in FABP7-overexpressing cell lines (SKRC7 and SKRC10). RESULTS Our immunohistochemical analysis showed that higher FABP7 expression significantly correlated with distant metastasis and poor cancer-specific survival (CSS; both p < 0.05). Functional suppression of FABP7 significantly inhibited SKRC10 cell growth (p < 0.05) and resulted in a significant reduction of the invasive potential (p < 0.01), but did not cause growth inhibition of SKRC7 cells. We found that The Cancer Genome Atlas Research Network (TCGA) database shows FABP6 and 7 as equally overexpressed in the FABP family. Functional suppression of fatty acid binding protein 6 (FABP6) resulted in significant growth inhibition of SKRC7 cells (p < 0.005). CONCLUSIONS Functional suppression of FABP7 significantly reduced cell viability and invasive potential in a ccRCC cell line. FABP7 may play a role in progression in some metastatic ccRCCs. The suppressed function may be compensated by another FABP family member.
Collapse
Affiliation(s)
- Kazuhiro Nagao
- Department of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1, Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan. .,Department of Urology, Radboud University Medical Center, Nijmegen 267 Experimental Urology, Geert Grooteplein, 26-28, P.O. Box 9101, NL-6525, GA, Nijmegen, The Netherlands.
| | - Nachi Shinohara
- Department of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1, Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan
| | - Frank Smit
- Department of Urology, Radboud University Medical Center, Nijmegen 267 Experimental Urology, Geert Grooteplein, 26-28, P.O. Box 9101, NL-6525, GA, Nijmegen, The Netherlands
| | - Mirjam de Weijert
- Department of Urology, Radboud University Medical Center, Nijmegen 267 Experimental Urology, Geert Grooteplein, 26-28, P.O. Box 9101, NL-6525, GA, Nijmegen, The Netherlands
| | - Sander Jannink
- Department of Urology, Radboud University Medical Center, Nijmegen 267 Experimental Urology, Geert Grooteplein, 26-28, P.O. Box 9101, NL-6525, GA, Nijmegen, The Netherlands
| | - Yuji Owada
- Department of Organ Anatomy, Tohoku University Graduate School of Medicine, 2-1, Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan
| | - Peter Mulders
- Department of Urology, Radboud University Medical Center, Nijmegen 267 Experimental Urology, Geert Grooteplein, 26-28, P.O. Box 9101, NL-6525, GA, Nijmegen, The Netherlands
| | - Egbert Oosterwijk
- Department of Urology, Radboud University Medical Center, Nijmegen 267 Experimental Urology, Geert Grooteplein, 26-28, P.O. Box 9101, NL-6525, GA, Nijmegen, The Netherlands
| | - Hideyasu Matsuyama
- Department of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1, Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan
| |
Collapse
|
43
|
van Valenberg FJP, Witjes JA, Aklan B, de Jong SF, Zegers H, Oosterwijk E. Inducing intravesical hyperthermia of the ex-vivo porcine bladder wall: radiofrequency-induction versus recirculation using a custom-made device. Int J Hyperthermia 2018; 35:323-329. [PMID: 30303406 DOI: 10.1080/02656736.2018.1499046] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
INTRODUCTION Several techniques can be used to treat intravesical chemohyperthermia (ChHT). We compared radiofrequency-induced hyperthermia (RF-HT) with conductive hyperthermia (C-HT) for their ability to induce bladder wall temperatures of >40.5 °C, the target temperature for ChHT. MATERIALS AND METHODS Fresh porcine bladders (n = 12) were placed in a temperature-controlled saline bath to simulate body temperature and circulation. HT was induced with RF-HT (43 °C) or C-HT (inflow temperature 44 and 46 °C) using a custom-made device. In two additional bladders, we varied intravesical solution and volume. Temperatures were recorded with a three-way catheter containing three mucosal and two urethral thermocouples (TCs) and a 915 MHz RF antenna, and with external TCs in the bladder wall at three different levels and three different locations. RESULTS Target temperature (40.5 °C) was reached in the submucosa at all locations by both techniques. In the detrusor, target temperature was reached by RF-HT at the bladder neck and side wall. C-HT46 reached significantly higher submucosal temperatures at the side wall. The bladder dome seemed best heated by C-HT, although a high inflow temperature (46 vs. 44 °C) was required (ns). Intravesical saline resulted in higher temperatures than sterile water for RF-HT. A volume of 100 mL resulted in higher bladder dome temperatures for RF-HT, and higher bladder neck with lower dome temperatures for C-HT. CONCLUSION Our results indicate a slightly superior heating capacity for RF-HT compared to C-HT, whereas for the bladder dome, the reverse seems true. Comparative studies are warranted to evaluate whether HT efficacy differs between both techniques, with emphasis on tumor location.
Collapse
Affiliation(s)
- F J P van Valenberg
- a Department of Urology , Radboud University Medical Center , Nijmegen , The Netherlands
| | - J A Witjes
- a Department of Urology , Radboud University Medical Center , Nijmegen , The Netherlands
| | - B Aklan
- b Department of Internal Medicine III , Ludwig Maximilians University Hospital , Munich , Germany
| | - S F de Jong
- c Department of Cardio-Thoracic Surgery , Radboud University Medical Center , Nijmegen , The Netherlands
| | - H Zegers
- c Department of Cardio-Thoracic Surgery , Radboud University Medical Center , Nijmegen , The Netherlands
| | - E Oosterwijk
- a Department of Urology , Radboud University Medical Center , Nijmegen , The Netherlands
| |
Collapse
|
44
|
Janke HP, Güvener N, Dou W, Tiemessen DM, YantiSetiasti A, Cremers JGO, Borm PJA, Feitz WFJ, Heerschap A, Kiessling F, Oosterwijk E. Labeling of Collagen Type I Templates with a Naturally Derived Contrast Agent for Noninvasive MR Imaging in Soft Tissue Engineering. Adv Healthc Mater 2018; 7:e1800605. [PMID: 30058274 DOI: 10.1002/adhm.201800605] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2018] [Revised: 06/26/2018] [Indexed: 12/14/2022]
Abstract
In vivo monitoring of tissue-engineered constructs is important to assess their integrity, remodeling, and degradation. However, this is challenging when the contrast with neighboring tissues is low, necessitating labeling with contrast agents (CAs), but current CAs have limitations (i.e., toxicity, negative contrast, label instability, and/or inappropriate size). Therefore, a naturally derived hemin-L-lysine (HL) complex is used as a potential CA to label collagen-based templates for magnetic resonance imaging (MRI). Labeling does not change the basic characteristics of the collagen templates. When hybrid templates composed of collagen type I reinforced with degradable polymers are subcutaneously implanted in mice, longitudinal visualization by MRI is possible with good contrast and in correlation with template remodeling. In contrast, unlabeled collagen templates are hardly detectable and the fate of these templates cannot be monitored by MRI. Interestingly, tissue remodeling and vascularization are enhanced within HL-labeled templates. Thus, HL labeling is presented as a promising universal imaging marker to label tissue-engineered implants for MRI, which additionally seems to accelerate tissue regeneration.
Collapse
Affiliation(s)
- Heinz P. Janke
- Department of Urology; Radboud Institute for Molecular Life Sciences; Radboud University Medical Center; Geert Grooteplein 28 6525 GA Nijmegen The Netherlands
| | - Nihan Güvener
- Institute for Experimental Molecular Imaging; Center for Biohybrid Medical Systems Uniklinik RWTH and Helmholtz Institute for Biomedical Engineering; RWTH Aachen University; Forckenbeckstr. 55 52074 Aachen Germany
- Nano4Imaging GmbH; Zentrum für Biomedizintechnik (ZBMT); Pauwelsstrasse 17 52074 Aachen Germany
| | - Weiqiang Dou
- Department of Radiology and Nuclear Medicine; Radboud University Medical Center; PO Box 9101 6500 HB Nijmegen The Netherlands
- GE Healthcare; MR Research China; Beijing 100176 China
| | - Dorien M. Tiemessen
- Department of Urology; Radboud Institute for Molecular Life Sciences; Radboud University Medical Center; Geert Grooteplein 28 6525 GA Nijmegen The Netherlands
| | - Anglita YantiSetiasti
- Department of Urology; Radboud Institute for Molecular Life Sciences; Radboud University Medical Center; Geert Grooteplein 28 6525 GA Nijmegen The Netherlands
- Department of Anatomical Pathology; Faculty of Medicine; University of Padjadjaran; Jalan Professor Eyckman No. 38; Bandung 4016 Indonesia
| | - Jozef G. O. Cremers
- Institute for Experimental Molecular Imaging; Center for Biohybrid Medical Systems Uniklinik RWTH and Helmholtz Institute for Biomedical Engineering; RWTH Aachen University; Forckenbeckstr. 55 52074 Aachen Germany
- Nano4Imaging GmbH; Zentrum für Biomedizintechnik (ZBMT); Pauwelsstrasse 17 52074 Aachen Germany
| | - Paul J. A. Borm
- Nano4Imaging GmbH; Zentrum für Biomedizintechnik (ZBMT); Pauwelsstrasse 17 52074 Aachen Germany
| | - Wout F. J. Feitz
- Department of Urology; Radboud Institute for Molecular Life Sciences; Radboud University Medical Center; Geert Grooteplein 28 6525 GA Nijmegen The Netherlands
- Radboudumc Amalia Children's Hospital; Radboud University Medical Center; Geert Grooteplein 28 6525 GA Nijmegen The Netherlands
| | - Arend Heerschap
- Department of Radiology and Nuclear Medicine; Radboud University Medical Center; PO Box 9101 6500 HB Nijmegen The Netherlands
| | - Fabian Kiessling
- Institute for Experimental Molecular Imaging; Center for Biohybrid Medical Systems Uniklinik RWTH and Helmholtz Institute for Biomedical Engineering; RWTH Aachen University; Forckenbeckstr. 55 52074 Aachen Germany
| | - Egbert Oosterwijk
- Department of Urology; Radboud Institute for Molecular Life Sciences; Radboud University Medical Center; Geert Grooteplein 28 6525 GA Nijmegen The Netherlands
| |
Collapse
|
45
|
Siddiqi S, de Wit R, van der Heide S, Oosterwijk E, Verhagen A. Aortic allografts: final destination?-a summary of clinical tracheal substitutes. J Thorac Dis 2018; 10:5149-5153. [PMID: 30233891 DOI: 10.21037/jtd.2018.07.108] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The patient population in desperate need for an airway substitute are individuals with long segment tracheal defects that are considered, technically, inoperable. Regardless of the underlying etiology, benign or malignant growing processes, this patient category enters a palliative setting or require tracheal transplantation. Different airway substitutes have been categorized by Grillo as follows; tracheal transplantation, autogenous tissue, non-viable tissue, tissue-engineering and foreign materials. These fields have been explored in the past in animal models and in clinical patients. Research on airway replacement has been exposed to a level of controversies in the past years. The field has been turbulent and apocryphal. In particular, the area of tissue-engineering using stem cells has suffered from a major set-back leaving scientists, clinicians and ethical committees skeptical. Recently, a hopeful study emerged using aortic allografts as tracheal substitutes in patients with airway defects. The initial results seem promising and reliable. The developments of the field at this point seem striking and hopeful. The focus of this review is to shed light on developments in the field of aortic allografts as substitute for tracheal replacement.
Collapse
Affiliation(s)
- Sailay Siddiqi
- Department of Cardiothoracic Surgery, Radboud Medical Center, Nijmegen, The Netherlands
| | - Rayna de Wit
- Department of Cardiothoracic Surgery, Radboud Medical Center, Nijmegen, The Netherlands
| | - Stefan van der Heide
- Department of Cardiothoracic Surgery, Radboud Medical Center, Nijmegen, The Netherlands
| | - Egbert Oosterwijk
- Department of Urology, Radboud Medical Center, Nijmegen, The Netherlands
| | - Ad Verhagen
- Department of Cardiothoracic Surgery, Radboud Medical Center, Nijmegen, The Netherlands
| |
Collapse
|
46
|
Sloff M, Janke HP, de Jonge PKJD, Tiemessen DM, Kortmann BBM, Mihaila SM, Geutjes PJ, Feitz WFJ, Oosterwijk E. The Impact of γ-Irradiation and EtO Degassing on Tissue Remodeling of Collagen-based Hybrid Tubular Templates. ACS Biomater Sci Eng 2018; 4:3282-3290. [PMID: 30221191 PMCID: PMC6134342 DOI: 10.1021/acsbiomaterials.8b00369] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Accepted: 07/25/2018] [Indexed: 12/16/2022]
Abstract
![]()
Clinical
implementation of novel products for tissue engineering
and regenerative medicine requires a validated sterilization method.
In this study, we investigated the effect of γ-irradiation and
EtO degassing on material characteristics in vitro and the effect on template remodeling of hybrid tubular constructs
in a large animal model. Hybrid tubular templates were prepared from
type I collagen and Vicryl polymers and sterilized by 25 kGray of
γ-irradiation or EtO degassing. The in vitro characteristics were extensively studied, including tensile strength
analysis and degradation studies. For in vivo evaluation,
constructs were subcutaneously implanted in goats for 1 month to form
vascularized neo-tissue. Macroscopic and microscopic appearances of
the γ- and EtO-sterilized constructs slightly differed due to
additional processing required for the COL-Vicryl-EtO constructs.
Regardless of the sterilization method, incubation in urine resulted
in fast degradation of the Vicryl polymer and decreased strength (<7
days). Incubation in SBF was less invasive, and strength was maintained
for at least 14 days. The difference between the two sterilization
methods was otherwise limited. In contrast, subcutaneous implantation
showed that the effect of sterilization was considerable. A well-vascularized
tube was formed in both cases, but the γ-irradiated construct
showed an organized architecture of vasculature and was mechanically
more comparable to the native ureter. Moreover, the γ-irradiated
construct showed advanced tissue remodeling as shown by enhanced ECM
production. This study shows that the effect of sterilization on tissue
remodeling cannot be predicted by in vitro analyses
alone. Thus, validated sterilization methods should be incorporated
early in the development of tissue engineered products, and this requires
both in vitro and in vivo analyses.
Collapse
Affiliation(s)
- Marije Sloff
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28 Zuid, 6525 GA Nijmegen, The Netherlands
| | - Heinz P Janke
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28 Zuid, 6525 GA Nijmegen, The Netherlands
| | - Paul K J D de Jonge
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28 Zuid, 6525 GA Nijmegen, The Netherlands
| | - Dorien M Tiemessen
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28 Zuid, 6525 GA Nijmegen, The Netherlands
| | - Barbara B M Kortmann
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28 Zuid, 6525 GA Nijmegen, The Netherlands.,Radboudumc Amalia Children's Hospital, Radboud University Medical Center, Geert Grooteplein 10 Zuid, 6525 GA Nijmegen, The Netherlands
| | - Silvia M Mihaila
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28 Zuid, 6525 GA Nijmegen, The Netherlands
| | - Paul J Geutjes
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28 Zuid, 6525 GA Nijmegen, The Netherlands
| | - Wout F J Feitz
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28 Zuid, 6525 GA Nijmegen, The Netherlands.,Radboudumc Amalia Children's Hospital, Radboud University Medical Center, Geert Grooteplein 10 Zuid, 6525 GA Nijmegen, The Netherlands
| | - Egbert Oosterwijk
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28 Zuid, 6525 GA Nijmegen, The Netherlands
| |
Collapse
|
47
|
de Jonge PK, Sloff M, Janke HP, Versteegden LR, Kortmann BB, de Gier RP, Geutjes PJ, Oosterwijk E, Feitz WF. Ureteral Reconstruction in Goats Using Tissue-Engineered Templates and Subcutaneous Preimplantation. Tissue Eng Part A 2018; 24:863-872. [PMID: 29105596 DOI: 10.1089/ten.tea.2017.0347] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Affiliation(s)
- Paul K.J.D. de Jonge
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Marije Sloff
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Heinz-Peter Janke
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Luuk R.M. Versteegden
- Department of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Barbara B.M. Kortmann
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
- Radboudumc Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Robert P.E. de Gier
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
- Radboudumc Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Paul J. Geutjes
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Egbert Oosterwijk
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Wout F.J. Feitz
- Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
- Radboudumc Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, The Netherlands
| |
Collapse
|
48
|
Falke J, Hulsbergen-van de Kaa CA, Maj R, Oosterwijk E, Witjes JA. A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model. World J Urol 2018; 36:1719-1725. [PMID: 29767328 PMCID: PMC6208681 DOI: 10.1007/s00345-018-2334-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Accepted: 05/08/2018] [Indexed: 12/20/2022] Open
Abstract
Purpose TMX-101 and TMX-202 are formulations of toll-like receptor 7 (TLR-7) agonists, under investigation for the treatment of urothelial carcinoma. Our goal was to evaluate the efficacy of intravesical instillations of TMX-101 or TMX-202 in an orthotopic bladder cancer rat model. Methods Four groups of 14 rats received an instillation with isogenic AY-27 tumor cells on day 0, starting tumor development. On day 2 and 5, the rats were treated with an intravesical instillation of TMX-101 0.1%, TMX-202 0.38%, vehicle solution or NaCl. On day 12 the rats were sacrificed and the bladders were evaluated histopathologically. Results No signs of toxicity were seen. The number of tumor-positive rats was 11 of 14 (79%) in the vehicle control group and in the NaCl control group, versus 9 of 14 (64%) in the TMX-101-treated group, and 8 of 14 (57%) in the TMX-20-treated group. The difference between tumor-bearing rats in the treated and control groups was not significant (p = 0.12). Bladder weight was significantly lower for TMX-202-treated rats compared to vehicle (p = 0.005). Conclusions TMX-101 and TMX-202 are TLR-7 agonists with antitumor activity. Treatment with TMX-101 and TMX-202 resulted in less tumor-bearing rats compared to vehicle or saline control groups, although not statistically significant. In this aggressive bladder cancer model, a lower number of tumor-positive rats after treatment with TLR-7 agonists indicates activity for the treatment of non-muscle invasive bladder cancer. Electronic supplementary material The online version of this article (10.1007/s00345-018-2334-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Johannes Falke
- Department of Urology, Radboud University Nijmegen Medical Center, Geert Grooteplein Zuid 10 (610), P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands
| | | | | | - Egbert Oosterwijk
- Department of Urology, Radboud University Nijmegen Medical Center, Geert Grooteplein Zuid 10 (610), P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands
| | - J Alfred Witjes
- Department of Urology, Radboud University Nijmegen Medical Center, Geert Grooteplein Zuid 10 (610), P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
| |
Collapse
|
49
|
van Valenberg FJP, Strauss-Ayali D, Agmon-Gerstein Y, Friedman A, Arentsen HC, Schaafsma HE, Witjes JA, Oosterwijk E. Assessment of the efficacy of repeated instillations of mitomycin C mixed with a thermosensitive hydrogel in an orthotopic rat bladder cancer model. Ther Adv Urol 2018; 10:213-221. [PMID: 30034540 PMCID: PMC6048623 DOI: 10.1177/1756287218762064] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2017] [Accepted: 02/02/2018] [Indexed: 11/25/2022] Open
Abstract
Background: We investigated a thermoreversible hydrogel that is highly viscous at body
temperature, while fluid-like at a low temperature, thus aiming for a slow
and prolonged intravesical drug release. Our study purposed to assess
antitumor efficacy of mitomycin C (MMC) mixed with hydrogel in an orthotopic
rat bladder cancer model. Methods: Bladders of female Fischer F344 rats were grafted with 1.5 × 106
AY-27 urothelial carcinoma cells. On day 5, tumor presence was assessed by
cystoscopy and rats were divided into six groups (five treatment, one
control, n = 10/group). Intravesical treatments (0.5 mg or
1 mg MMC-H2O or MMC-hydrogel, or 2 mg MMC-hydrogel) were
administered on days 5, 8 and 11. Rats were sacrificed at day 14 and
bladders were evaluated. Results: Rats with tumor at cystoscopy (47/60) were evaluated for efficacy. At
necropsy, all control animals (8/8) had tumors. No microscopic tumors were
present in the 0.5 mg and 1 mg MMC-hydrogel groups compared with 2/8 and 1/8
rats in the 0.5 mg and 1 mg MMC-H2O groups (p =
0.47 and p = 1.00, respectively). Greater toxicity was seen in animals treated with MMC-hydrogel compared with
MMC-H2O, as demonstrated by lower body weights at necropsy
(p = 0.000) and a tendency for more severe clinical
signs in the 1 and 2 mg MMC-hydrogel groups. Rats that died prematurely
received 1 mg (4/10) or 2 mg (9/10) of MMC-hydrogel. Conclusions: Under the current model conditions it is unclear whether instillation of
MMC-hydrogel is more effective than MMC-H2O. Nonetheless, the
observed difference in toxicity, acting as a surrogate marker for systemic
MMC exposure in the MMC-hydrogel-treated rats, supports the prolonged drug
release mechanism of the hydrogel.
Collapse
Affiliation(s)
- F Johannes P van Valenberg
- Department of Urology, Radboud University Medical Center, Geert Grooteplein 26-28 (267), PO Box 9101, 6500 HB Nijmegen, The Netherlands
| | | | | | | | | | - H Ewout Schaafsma
- Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - J Alfred Witjes
- Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Egbert Oosterwijk
- Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
| |
Collapse
|
50
|
Hekman MC, Rijpkema M, Muselaers CH, Oosterwijk E, Hulsbergen-Van de Kaa CA, Boerman OC, Oyen WJ, Langenhuijsen JF, Mulders PF. Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study. Theranostics 2018; 8:2161-2170. [PMID: 29721070 PMCID: PMC5928878 DOI: 10.7150/thno.23335] [Citation(s) in RCA: 75] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2017] [Accepted: 02/09/2018] [Indexed: 12/21/2022] Open
Abstract
Intraoperative imaging with antibodies labeled with both a radionuclide for initial guidance and a near-infrared dye for adequate tumor delineation may overcome the main limitation of fluorescence imaging: the limited penetration depth of light in biological tissue. In this study, we demonstrate the feasibility and safety of intraoperative dual-modality imaging with the carbonic anhydrase IX (CAIX)-targeting antibody 111In-DOTA-girentuximab-IRDye800CW in clear cell renal cell carcinoma (ccRCC) patients. Methods: A phase I protein dose escalation study was performed in patients with a primary renal mass who were scheduled for surgery. 111In-DOTA-girentuximab-IRDye800CW (5, 10, 30, or 50 mg, n=3 ccRCC patients per dose level) was administered intravenously and after 4 days SPECT/CT imaging was performed. Seven days after antibody injection, surgery was performed with the use of a gamma probe and near-infrared fluorescence camera. Results: In total, fifteen patients were included (12 ccRCC, 3 CAIX-negative tumors). No study-related serious adverse events were observed. All ccRCC were visualized by SPECT/CT and localized by intraoperative gamma probe detection (mean tumor-to-normal kidney (T:N) ratio 2.5 ± 0.8), while the T:N ratio was 1.0 ± 0.1 in CAIX-negative tumors. ccRCC were hyperfluorescent at all protein doses and fluorescence imaging could be used for intraoperative tumor delineation, assessment of the surgical cavity and detection of (positive) surgical margins. The radiosignal was crucial for tumor localization in case of overlying fat tissue. Conclusion: This first in man study shows that tumor-targeted dual-modality imaging using 111In-DOTA-girentuximab-IRDye800CW is safe and can be used for intraoperative guidance of ccRCC resection.
Collapse
|